<SEC-DOCUMENT>0001193125-20-166621.txt : 20200611
<SEC-HEADER>0001193125-20-166621.hdr.sgml : 20200611
<ACCEPTANCE-DATETIME>20200611160213
ACCESSION NUMBER:		0001193125-20-166621
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20200610
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200611
DATE AS OF CHANGE:		20200611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CareDx, Inc.
		CENTRAL INDEX KEY:			0001217234
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				943316839
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36536
		FILM NUMBER:		20957181

	BUSINESS ADDRESS:	
		STREET 1:		1 TOWER PLACE
		STREET 2:		9TH FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-287-2300

	MAIL ADDRESS:	
		STREET 1:		1 TOWER PLACE
		STREET 2:		9TH FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XDx, Inc.
		DATE OF NAME CHANGE:	20071010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXPRESSION DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20030203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d923446d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdna="http://www.caredxinc.com/20200610" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-06-10_to_2020-06-10">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-06-10_to_2020-06-10">0001217234</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="cdna-20200610.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-06-10_to_2020-06-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-10</xbrli:startDate> <xbrli:endDate>2020-06-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Washington, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:12pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-06-10_to_2020-06-10">8-K</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt:datemonthdayyearen">June 10, 2020</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:12pt"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-06-10_to_2020-06-10">CAREDX, INC.</ix:nonNumeric> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact Name of Registrant as Specified in its Charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-06-10_to_2020-06-10">001-36536</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-06-10_to_2020-06-10">94-3316839</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or Other Jurisdiction</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">of Incorporation)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(IRS Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-06-10_to_2020-06-10">1 Tower Place</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-06-10_to_2020-06-10">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-06-10_to_2020-06-10">94080</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of Principal Executive Offices) (Zip Code)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-06-10_to_2020-06-10">(415)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-06-10_to_2020-06-10">287-2300</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Registrant&#8217;s telephone number, including area code</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">N/A</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Former Name, or Former Address, if Changed Since Last Report)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&#160;</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))&#160;</td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section 12(b) of the Exchange Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Title of each class)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Name of exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered)</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-06-10_to_2020-06-10">Common Stock, $0.001 Par Value</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-06-10_to_2020-06-10">CDNA</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="font-family:Times New Roman;text-align:right;font-size:10pt;margin-bottom:0px;margin-top:12pt">Emerging growth company&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-06-10_to_2020-06-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:8pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;1.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Entry into a Material Definitive Agreement.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">On June&#160;10, 2020, CareDx, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Goldman Sachs&#160;&#038; Co. LLC and Jefferies LLC (the &#8220;Representatives&#8221;), acting as joint book-running managers and representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), relating to an underwritten public offering (the &#8220;Offering&#8221;) of 3,906,250 shares of the Company&#8217;s common stock, $0.001 par value per share (&#8220;Common Stock&#8221;). The public offering price is $32.00 per share of Common Stock and the Underwriters have agreed to purchase the Common Stock pursuant to the Underwriting Agreement at a price of $30.08 per share. Under the terms of the Underwriting Agreement, the Company also granted to the Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional 585,937 shares of Common Stock at the public offering price.&#160;</p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Offering is being made pursuant to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-3ASR</span> (File No.<span style="white-space:nowrap">&#160;333-239049),</span> filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June&#160;9, 2020, which became effective immediately upon filing, including a base prospectus dated June&#160;9, 2020, and a prospectus supplement dated June&#160;10, 2020. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Net proceeds from the Offering are expected to be approximately $117.1&#160;million (excluding any sale of shares of Common Stock pursuant to the option to purchase additional shares granted to the Underwriters), after deducting underwriting discounts and commissions and estimated Offering expenses payable by the Company. The purchase and sale of the Common Stock, and the closing of the Offering, is expected to take place on or about June&#160;15, 2020, subject to the satisfaction of customary closing conditions. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Underwriting Agreement contains customary representations, warranties and covenants made by the Company. It also provides for customary indemnification by each of the Company and the Underwriters, severally and not jointly, for losses or damages arising out of or in connection with the Offering, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement, each of the Company&#8217;s directors and executive officers have entered into <span style="white-space:nowrap">&#8220;lock-up&#8221;</span> agreements with the Underwriters that generally prohibit, without the prior written consent of the Representatives, the sale, transfer or other disposition of securities of the Company prior to September&#160;9, 2020, except for sales pursuant to a trading plan meeting the requirements of Rule <span style="white-space:nowrap">10b5-1</span> under the Securities Exchange Act of 1934, as amended, that was in effect as of the date of the Underwriting Agreement. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the copy of the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> A copy of the opinion of Paul Hastings LLP, counsel to the Company, relating to the validity of the shares of Common Stock to be issued in the Offering is filed with this Current Report on Form<span style="white-space:nowrap">&#160;8-K</span> as Exhibit&#160;5.1. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Underwriting Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Underwriting Agreement, and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC. </p> <p style="font-family:Times New Roman;font-style:italic;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt">Forward-Looking Statements </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements that involve risks and uncertainties, such as statements related to the anticipated closing of the Offering and the amount of proceeds expected from the Offering. The risks and uncertainties involved include the Company&#8217;s ability to satisfy certain conditions to closing on a timely basis or at all, market conditions, and other risks detailed from time to time in the Company&#8217;s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company&#8217;s current expectations and assumptions and speak only as of the date of this Current Report on Form <span style="white-space:nowrap">8-K.</span> The Company does not intend to revise or update any forward-looking statement in this Current Report on Form <span style="white-space:nowrap">8-K</span> as a result of new information, future events or otherwise, except as required by law. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;8.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Other Events.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">On June&#160;10, 2020, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d) Exhibits. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="white-space:nowrap;vertical-align:bottom;text-align:center;"> <p style="font-family:Times New Roman;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">Number</p> </td>
<td style="white-space:nowrap;vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;display:inline-block;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:left;"> <p style="font-family:Times New Roman;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">Description</p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;1.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d923446dex11.htm">Underwriting Agreement, dated as of June&#160;10, 2020, by and among CareDx, Inc. and Goldman Sachs&#160;&#038; Co. LLC and Jefferies LLC as the representatives of the underwriters named therein. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;5.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d923446dex51.htm">Opinion of Paul Hastings LLP. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">23.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d923446dex51.htm">Consent of Paul Hastings LLP (included in Exhibit 5.1). </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d923446dex991.htm">Press Release, dated June&#160;10, 2020. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:46%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:2%;"></td>
<td style="width:1%;"></td>
<td style="width:45%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date: June&#160;11, 2020 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">CAREDX, INC. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ Michael Bell </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Michael Bell </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Chief Financial Officer </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>
 </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d923446dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3,906,250 Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CareDx, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">June&nbsp;10, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO.
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several
Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B>
CareDx, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in <U>Schedule A</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of 3,906,250 shares (the
&#147;<B>Shares</B>&#148;) of its common stock, par value $0.001 per share (the &#147;<B>Common Stock</B>&#148;<B>)</B>. The 3,906,250 Shares to be sold by the Company are called the &#147;<B>Firm Shares</B>.&#148; In addition, the Company has
granted to the Underwriters an option to purchase up to an additional 585,937 Shares as provided in Section&nbsp;2. The additional 585,937 Shares to be sold by the Company pursuant to such option are collectively called the &#147;<B>Optional
Shares</B>.&#148; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the &#147;<B>Offered Shares</B>.&#148; Goldman Sachs&nbsp;&amp; Co. LLC (&#147;<B>Goldman</B>&#148;) and<B>
</B>Jefferies LLC (&#147;<B>Jefferies</B>&#148;) have agreed to act as representatives of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Shares. To the
extent there are no additional underwriters listed on <U>Schedule A</U>, the term &#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural, as the
context requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a
shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3ASR,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-239049,</FONT> including a base prospectus (the &#147;<B>Base Prospectus</B>&#148;) to be used in connection
with the public offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including all documents incorporated or deemed to be incorporated by reference therein and any information deemed to be a part
thereof at the time of effectiveness pursuant to Rule&nbsp;430A or 430B under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities
Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the date and time of filing of any such Rule 462(b) Registration Statement the term
&#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The preliminary prospectus supplement dated June&nbsp;9, 2020 describing the Offered Shares and the offering thereof (the &#147;<B>Preliminary Prospectus
Supplement</B>&#148;), together with the Base Prospectus, is </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other prospectus supplement to the Base Prospectus in preliminary form that describes the Offered
Shares and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#147;<B>preliminary prospectus</B>.&#148; As used herein, the term &#147;<B>Prospectus</B>&#148;
shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Shares and the offering thereof (the &#147;<B>Final Prospectus Supplement</B>&#148;), together with the Base Prospectus, in the form first used by the
Underwriters to confirm sales of the Offered Shares<B> </B>or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act. References herein to the Preliminary
Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such prospectus. As used herein, &#147;<B>Applicable Time</B>&#148; is 5:45 p.m. (New York City time) on
June 10, 2020. As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148; means the Preliminary Prospectus, as amended or supplemented
immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto. As used herein, <B>&#147;Road Show&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the
Securities Act) relating to the offering of the Offered Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). As used herein, &#147;<B><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communication</B>&#148; means each written communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on Rule 163B of the Securities Act by the
Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (&#147;QIBs&#148;) and/or institutions that are accredited investors (&#147;<B>IAIs</B>&#148;), as such terms
are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Shares;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Oral Communication&#148; means each oral communication, if any, made in reliance on Rule 163B of the Securities Act by the Company or any person
authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Shares; &#147;<B>Marketing Material</B>&#148; means any materials
or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Shares, including any roadshow or investor presentations made to investors by the Company (whether in
person or electronically); and &#147;Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communication(s) and Marketing Materials listed on <U>Schedule C</U> attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus
and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other information which are &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the
Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule
462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements to the
Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;) that is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any
preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement to (i)&nbsp;the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus or the
Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System
(&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; provided for use in connection with the offering of the Offered Shares as contemplated by Section&nbsp;3(n) of this Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreements with the Underwriters as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. Representations and Warranties of the Company.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as
hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Compliance with
Registration Requirements</I></B><B>.</B> The Registration Statement has become effective under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction, with all requests of the Commission for additional or supplemental
information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or
threatened by the Commission. At the time the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 (the &#147;<B>Annual Report</B>&#148;) was filed with the Commission, or, if
later, at the time the Registration Statement was originally filed with the Commission, as well as at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Securities Act) made
any offer relating to the Offered Shares in reliance on the exemption of Rule 163 under the Securities Act, the Company was a &#147;well known seasoned issuer&#148; as defined in Rule 405 under the Securities Act. The Registration Statement is an
&#147;automatic shelf registration statement,&#148; as defined in Rule 405 under the Securities Act, and became effective on June&nbsp;9, 2020. The Company has not received from the Commission any notice pursuant to Rule 401(g)(2) under the
Securities Act objecting to the Company&#146;s use of the automatic shelf registration form. The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act specified in the Financial Industry
Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;) Conduct Rule 5110(B)(7)(C)(i). The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they
were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the Exchange Act. The Company is not a shell company (as
defined in Rule 405 under the Securities Act) and has never been a shell company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Disclosure</I></B><B>.</B> Each
preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement and any
post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus (including any Prospectus wrapper) did not, and at the First Closing Date (as defined in
Section&nbsp;2) and at each applicable Option Closing Date (as defined in Section&nbsp;2), will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The Prospectus (including any Prospectus wrapper)<B>,</B> as of its date, did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three
immediately preceding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments
or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only
such information consists of the information described in Section&nbsp;9(b) below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration
Statement which have not been described or filed as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses; Road Show</I></B><B>.</B> As of
the determination date referenced in Rule 164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of the Offered Shares pursuant to Rules 164, 405
and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the
Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply
in all material respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission, retention and legending, as applicable, and each such free writing prospectus, as of its issue date and at all
subsequent times through the completion of the public offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration
Statement, the Prospectus or any preliminary prospectus unless such information has been superseded or modified as of such time. Except for the free writing prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any,
furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of
Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Distribution of Offering Material By the Company</I></B><B>.</B> Prior to the later of (i)&nbsp;the
expiration or termination of the option granted to the several Underwriters in Section&nbsp;2 and (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Shares<B>,</B> the Company has not distributed and will not distribute
any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by the Representatives,
the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>The Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>No Applicable Registration or Other Similar Rights</I></B><B>.</B> There are no persons with registration or other
similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Financial </I></B><B><I>Information</I></B><B>.</B> The consolidated financial statements of the Company included or
incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, together with the related notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company and
the Subsidiaries (as defined below) as of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders&#146; equity of the Company for the periods specified and have been prepared in compliance in all
material respects with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements of the Securities Act and Exchange Act and in conformity with GAAP (as defined below) applied on a consistent basis during the periods involved; the other financial and statistical
data with respect to the Company and the Subsidiaries (as defined below) contained or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus are accurately and fairly presented and prepared in all
material respects on a basis consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included or incorporated by reference in the Registration
Statement, the Time of Sale Prospectus or the Prospectus that are not included or incorporated by reference as required; the Company and the Subsidiaries (as defined below) do not have any material liabilities or obligations, direct or contingent
(including any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), the Time of Sale Prospectus and the Prospectus; and all disclosures contained or
incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by the rules and regulations
of the Commission) comply, in all material respects, with Regulation G of the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, to the extent applicable. The interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance
with the Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Organization</I></B>. The Company and each of its
Subsidiaries (as defined below) are duly organized, validly existing as a corporation and in good standing (or equivalent) under the laws of their respective jurisdictions of organization. The Company and each of its Subsidiaries are duly licensed
or qualified as a foreign corporation for transaction of business and in good standing (or equivalent) under the laws of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses
requires such license or qualification, and have all corporate power and authority necessary to own or hold their respective properties and to conduct their respective businesses as described in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a
material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&#146; equity or results of operations of the Company and the Subsidiaries taken as a whole,
or prevent or materially interfere with consummation of the transactions contemplated hereby (a &#147;<B>Material Adverse Effect</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Subsidiaries</I></B>. The subsidiaries set forth on <U>Schedule D</U> (collectively, the &#147;<B>Subsidiaries</B>&#148;),
are the Company&#146;s only significant subsidiaries (as such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> promulgated by the Commission). Except as set forth in the
Registration Statement, the Time of Sale Prospectus and in the Prospectus, the Company owns, directly or indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first
refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and similar rights. No Subsidiary is currently prohibited, directly or indirectly, from paying
any dividends to the Company, from making any other distribution on such Subsidiary&#146;s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or, except in the case of CareDx International AB, from
transferring any of such Subsidiary&#146;s property or assets to the Company or any other Subsidiary of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>No
Violation or Default</I></B>. Neither the Company nor any of its Subsidiaries is (i)&nbsp;in violation of its charter or bylaws or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time
or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the property
or assets of the Company or any of its Subsidiaries are subject (each, an &#147;<B>Existing Instrument</B>&#148;); or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental
or regulatory authority, except, in the case of each of clauses (ii)&nbsp;and (iii) above, for any such violation or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the
Company&#146;s knowledge, no other party under any material contract or other agreement to which it or any of its Subsidiaries is a party is in default in any respect thereunder where such default would have a Material Adverse Effect. The
Company&#146;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Offered
Shares (including the use of proceeds from the sale of the Offered Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;<B>Use of Proceeds</B>&#148;) (i) have been duly authorized
by all necessary corporate action and will not result in any violation of the provisions of the charter or bylaws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any Subsidiary
(ii)&nbsp;will not conflict with or constitute a breach of, or default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the
Company or any of its Subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii)&nbsp;will not result in any violation of any law or statute or any judgment, order, rule or regulation of any court or
arbitrator or governmental or regulatory authority applicable to the Company or any of its Subsidiaries, except for such conflicts, breaches, defaults or Debt Repayment Triggering Events or liens, charges or encumbrances specified in clause
(ii)&nbsp;and (iii) above that would not, individually or in the aggregate, result in a Material Adverse Effect. As used herein, a &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition which gives, or with the giving of
notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>No Material Adverse Change</I></B>. Subsequent to the respective
dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus (including any document deemed incorporated by reference therein), there has not been (i)&nbsp;any Material Adverse Effect or the
occurrence of any development that the Company reasonably expects will result in a Material Adverse Effect, (ii)&nbsp;any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii)&nbsp;any obligation or liability,
direct or contingent (including any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations), incurred by the Company or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv)&nbsp;any material
change in the capital stock or outstanding long-term indebtedness of the Company or any of its Subsidiaries (other than pursuant to the terms of this Agreement) or (v)&nbsp;any dividend or distribution of any kind declared, paid or made on the
capital stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business or as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus or Prospectus (including any document deemed
incorporated by reference therein) (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>
<B><I>Capitalization</I></B>. The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and nonassessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject
to any preemptive rights, rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus as of the dates
referred to therein (other than the grant of additional options, restricted stock units or other equity awards under the Company&#146;s existing equity plans or the sale of shares under the Company&#146;s existing employee stock purchase plan, or
changes in the number of outstanding shares of Common Stock of the Company due to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof) and such authorized capital stock conforms
in all material respects to the description thereof set forth in the Registration Statement and the Prospectus. The description of the securities of the Company in the Registration Statement, the Time of Sale Prospectus and the Prospectus is
complete and accurate in all material respects. Except as disclosed in or contemplated by the Registration Statement, the Time of Sale Prospectus or the Prospectus, as of the date referred to therein, the Company does not have outstanding any
options to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or other securities. The
descriptions of the Company&#146;s stock option, stock bonus and other equity plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus
accurately and fairly present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Authorization; Enforceability</I></B>. The Company has full legal right, power and authority to enter into this Agreement and
perform the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent
that enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#146; rights generally and by general equitable principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Authorization of Offered Shares</I></B>. The Offered Shares have been duly authorized for issuance and sale pursuant to this
Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, free and clear of any pledge, lien, encumbrance, security interest or other claim,
including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares. The Offered Shares, when issued, will conform in all material respects to the
description thereof set forth in or incorporated into the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>No Consents
Required</I></B>. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this
Agreement and the consummation of the transactions contemplated by the Registration Statement, the Time of Sale Prospectus and the Prospectus, including the issuance and sale by the Company of the Offered Shares, except for such consents, approvals,
authorizations, orders and registrations or qualifications as may be required under the Securities Act and applicable state securities laws that are in full force and effect under the Securities Act or by the bylaws and rules of FINRA or the
Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>No Preferential Rights</I></B>. Except as set forth in the Registration Statement, the Time of Sale Prospectus
and the Prospectus, or except as otherwise waived in writing prior to the date hereof, (i)&nbsp;no person, as such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT>
promulgated under the Securities Act (each, a &#147;<B>Person</B>&#148;), has the right, contractual or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other capital stock or other securities of the
Company, (ii)&nbsp;no Person has any preemptive rights, resale rights, rights of first refusal, rights of <FONT STYLE="white-space:nowrap">co-sale,</FONT> or any other rights (whether pursuant to a &#147;poison pill&#148; provision or otherwise) to
purchase any Common Stock or shares of any other capital stock or other securities of the Company, (iii)&nbsp;no Person has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the
Offered Shares, and (iv)&nbsp;no Person has the right, contractual or otherwise, to require the Company to register under the Securities Act any Common Stock or shares of any other capital stock or other securities of the Company, or to include any
such shares or other securities in the Registration Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Offered Shares as contemplated thereby or
otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>Independent Public Accounting Firms</I></B>. Deloitte&nbsp;&amp; Touche LLP
(the &#147;<B>Accountant</B>&#148;) is an independent registered public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States). To the Company&#146;s knowledge, the Accountant is
not and was not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the &#147;<B>Sarbanes-Oxley Act</B>&#148;) with respect to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>Enforceability of Agreements</I></B>. All agreements between the Company and third parties expressly referenced in the
Registration Statement, the Time of Sale Prospectus and the Prospectus are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent that (i)&nbsp;enforceability may be limited by
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#146; rights generally and by general equitable principles and (ii)&nbsp;the indemnification provisions of certain agreements may be limited by federal or state
securities laws or public policy considerations in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>No Litigation</I></B>. Except as set forth in the
Registration Statement, the Time of Sale Prospectus or the Prospectus, there are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company&#146;s knowledge, any legal, governmental or regulatory audits or
investigations, to which the Company or a Subsidiary is a party or to which any property of the Company or any of its Subsidiaries is the subject that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect
and, to the Company&#146;s knowledge, no such actions, suits or proceedings are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending legal, governmental or
regulatory audits or investigations, actions, suits or proceedings that are required under the Securities Act to be described in the Prospectus that are not so described; and (ii)&nbsp;there are no contracts or other documents that are required
under the Securities Act to be filed as exhibits to the Registration Statement that are not so filed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Health Care
Authorizations</I></B>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or
amendments thereto issued or required by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct its business, including, without limitation, all such certificates, authorizations and permits required by the
United States Food and Drug Administration (the &#147;<B>FDA</B>&#148;), the United States Department of Health and Human Services (&#147;<B>HHS</B>&#148;), the United States Centers for Medicare&nbsp;&amp; Medicaid Services
(&#147;<B>CMS</B>&#148;), the European Medicines Agency (&#147;<B>EMEA</B>&#148;), Health Canada or any other state, federal or foreign agencies or bodies engaged in the regulation of medical devices (including diagnostic products), drugs or
biohazardous materials, and the Company have not received any notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such license, certificate, authorization or
permit, except for such registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits, the lack of which would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>Compliance with Health Care Laws</I></B>. The Company and, to the Company&#146;s knowledge, its directors, employees and
agents (while acting in such capacity) are in material compliance with, all health care laws applicable to the Company, or any of its products or activities, including, but not limited to, the federal Anti-Kickback Statute (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Anti-Inducement Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a(a)(5)),</FONT> the civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the
administrative False Claims Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> the Stark law (42 U.S.C. Section&nbsp;1395nn), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C.
Section&nbsp;1320d et seq.) as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the exclusion laws (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Controlled
Substances Act (21 U.S.C. Section&nbsp;801 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Section&nbsp;263a), Medicare (Title XVIII of the Social
Security Act), Medicaid (Title XIX of the Social Security Act), and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated pursuant to such laws,
and any other state, federal or foreign law, accreditation standards, regulation, memorandum, opinion letter, or other issuance which imposes requirements on the manufacturing, development, testing, labeling, advertising, marketing or distribution
of drugs and medical devices (including diagnostic products), kickbacks, patient or program charges, recordkeeping, claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or
supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, clinical laboratory or diagnostics products or services
(collectively, &#147;<B>Health Care Laws</B>&#148;). The Company has not received any notification, correspondence or any other written or oral communication, including notification of any pending or threatened claim, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any governmental authority, including, without limitation, the FDA, the EMEA, Health Canada, the United States Federal Trade Commission, the United States Drug Enforcement Administration
(&#147;<B>DEA</B>&#148;), CMS, HHS&#146;s Office of Inspector General, the United States Department of Justice and state Attorneys General or similar agencies of potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or
liability of, the Company under any Health Care Laws, except, with respect to any of the foregoing, such as would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&#146;s knowledge, there are no facts or
circumstances that would reasonably be expected to give rise to material liability of the Company under any Health Care Laws. The statements with respect to Health Care Laws and the Company&#146;s compliance therewith included in the Registration
Statement, the Time of Sale Prospectus and the Prospectus fairly summarize the matters therein described. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>Intellectual
Property</I></B>. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company and its Subsidiaries own, possess, license or have other rights to use all foreign and domestic patents, patent
applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, Internet domain names, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual
property (collectively, the &#147;<B>Intellectual Property</B>&#148;), necessary for the conduct of their respective businesses as now conducted except to the extent that the failure to own, possess, license or otherwise hold adequate rights to use
such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus (i)&nbsp;to the Company&#146;s knowledge, there
are no rights of third parties to any such Intellectual Property owned by the Company and its Subsidiaries; (ii)&nbsp;to the Company&#146;s knowledge, there is no infringement by third parties of any such Intellectual Property; (iii)&nbsp;there is
no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the Company&#146;s and its Subsidiaries&#146; rights in or to any such Intellectual Property, and the Company is unaware of any facts
which could form a reasonable basis for any such action, suit, proceeding or claim; (iv)&nbsp;there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any
such Intellectual Property; (v)&nbsp;there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others that the Company and its Subsidiaries infringe or otherwise violate any patent, trademark,
copyright, trade secret or other proprietary rights of others; (vi)&nbsp;to the Company&#146;s knowledge, there is no third-party U.S. patent or published U.S. patent application which contains claims for which an Interference Proceeding (as defined
in 35 U.S.C. &#167; 135) has been commenced against any patent or patent application described in the Prospectus as being owned by or licensed to the Company; and (vii)&nbsp;the Company and its Subsidiaries have complied with the terms of each
agreement pursuant to which Intellectual Property has been licensed to the Company or such Subsidiary, and all such agreements are in full force and effect, except, in the case of any of clauses (i)-(vii) above, for any such infringement by third
parties or any such pending or threatened suit, action, proceeding or claim as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B><I>Clinical Trials</I></B>. The studies, tests and preclinical and clinical
trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Prospectus or the Prospectus, or the results of which are referred to in
the Registration Statement, the Time of Sale Prospectus or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted
professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical
device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Prospectus
or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement,
the Time of Sale Prospectus or Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Prospectus or the Prospectus;
and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority
requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the
Company&#146;s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there has not been any violation of law or regulation by the Company in its
respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B><I>No Material Defaults</I></B>. Neither the Company nor any of the Subsidiaries has defaulted on any installment on
indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. The Company has not filed a report pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act since the filing of its last Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> indicating that it (i)&nbsp;has failed to pay any dividend or sinking fund installment on preferred
stock or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B><I>Certain Market Activities</I></B>. Neither the Company, nor any of the Subsidiaries, nor any of their respective
directors, officers or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or might reasonably be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation
of the price of the Common Stock or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (&#147;<B>Regulation M</B>&#148;)) with respect to the Common Stock, whether to facilitate the sale or resale of
the Offered Shares or otherwise, or taken any other action which would directly or indirectly violate Regulation M. The Common Stock is an &#147;actively traded security&#148; (as defined in Regulation M). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> <B><I>Broker/Dealer Relationships</I></B>. Neither the Company nor any of the Subsidiaries (i)&nbsp;is required to register as a
&#147;broker&#148; or &#147;dealer&#148; in accordance with the provisions of the Exchange Act or (ii)&nbsp;directly or indirectly through one or more intermediaries, controls or is a &#147;person associated with a member&#148; or &#147;associated
person of a member&#148; (within the meaning set forth in the FINRA Manual). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> <B><I>No Reliance</I></B>. The Company has not relied upon the Underwriters or
legal counsel for the Underwriters for any legal, tax or accounting advice in connection with the offering and sale of the Offered Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> <B><I>Taxes</I></B>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which
have been required to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good faith, except where the failure to so file or pay would not have a Material
Adverse Effect. Except as otherwise disclosed in or contemplated by the Registration Statement, the Time of Sale Prospectus or the Prospectus, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had,
or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been or might be asserted
or threatened against it which would have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> <B><I>Title to Real and Personal Property</I></B>.
Except as set forth in the Registration Statement, the Time of Sale Prospectus or the Prospectus, the Company and its Subsidiaries have good and marketable title in fee simple to all items of real property owned by them, good and valid title to all
personal property described in the Registration Statement, the Time of Sale Prospectus or Prospectus as being owned by them that are material to the businesses of the Company or such Subsidiary, in each case free and clear of all liens, encumbrances
and claims, except those matters that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries or (ii)&nbsp;would not reasonably be expected to, individually or in the
aggregate, have a Material Adverse Effect. Any real or personal property described in the Registration Statement, the Time of Sale Prospectus or Prospectus as being leased by the Company and any of its Subsidiaries is held by them under valid,
existing and enforceable leases, except those that (A)&nbsp;do not materially interfere with the use made or proposed to be made of such property by the Company or any of its Subsidiaries or (B)&nbsp;would not be reasonably expected, individually or
in the aggregate, to have a Material Adverse Effect. Each of the properties of the Company and its Subsidiaries complies with all applicable codes, laws and regulations (including, without limitation, building and zoning codes, laws and regulations
and laws relating to access to such properties), except if and to the extent disclosed in the Registration Statement, the Time of Sale Prospectus or Prospectus or except for such failures to comply that would not, individually or in the aggregate,
reasonably be expected to interfere in any material respect with the use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect. None of the Company or its subsidiaries has
received from any governmental or regulatory authorities any notice of any condemnation of, or zoning change affecting, the properties of the Company and its Subsidiaries, and the Company knows of no such condemnation or zoning change which is
threatened, except for such that would not reasonably be expected to interfere in any material respect with the use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect,
individually or in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> <B><I>Environmental Laws</I></B>. Except as set forth in the Registration Statement, the
Time of Sale Prospectus or the Prospectus, the Company and its Subsidiaries (i)&nbsp;are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human
health and safety, the environment or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of hazardous or toxic substances or wastes, pollutants or contaminants (collectively,
&#147;<B>Environmental Laws</B>&#148;); (ii) have received and are in compliance with all permits, licenses or other approvals required of them under applicable Environmental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Laws to conduct their respective businesses as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus; and (iii)&nbsp;have not received notice of any actual or
potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses (i), (ii) or (iii)&nbsp;above, for any such failure to
comply or failure to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> <B><I>Disclosure Controls</I></B>. The Company and each of its Subsidiaries maintain systems of internal accounting controls
sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company&#146;s internal control over financial reporting is effective and the
Company is not aware of any material weaknesses in its internal control over financial reporting (other than as set forth in the Prospectus). Since the date of the latest audited financial statements of the Company included in the Prospectus, there
has been no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting (other than as set forth in
the Prospectus). The Company has established disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15)</FONT> for the Company and designed such
disclosure controls and procedures to ensure that material information relating to the Company and each of its Subsidiaries is made known to the certifying officers by others within those entities, particularly during the period in which the
Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as the case may be, is being prepared. The Company&#146;s certifying officers have evaluated
the effectiveness of the Company&#146;s controls and procedures as of a date within 90 days prior to the filing date of the Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year most recently ended (such date, the &#147;<B>Evaluation
Date</B>&#148;). The Company presented in its Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date and the disclosure controls and procedures are effective. Since the Evaluation Date, there have been no significant changes in the Company&#146;s internal controls (as such term is defined in Item
307(b) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act) or, to the Company&#146;s knowledge, in other factors that could significantly affect the Company&#146;s internal controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> <B><I>Sarbanes-Oxley</I></B>. There is and has been no failure on the part of the Company or any of the Company&#146;s directors
or officers, in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder. Each of the principal executive officer and the principal
financial officer of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley
Act with respect to all reports, schedules, forms, statements and other documents required to be filed by it or furnished by it to the Commission. For purposes of the preceding sentence, &#147;principal executive officer&#148; and &#147;principal
financial officer&#148; shall have the meanings given to such terms in the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> <B><I>Finder&#146;s
Fees</I></B>. Neither the Company nor any of the Subsidiaries has incurred any liability for any finder&#146;s fees, brokerage commissions or similar payments in connection with the transactions herein contemplated, except as may otherwise exist
with respect to the Underwriters pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> <B><I>Labor Disputes</I></B>. No labor disturbance by or dispute with employees
of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is threatened which would reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Investment Company Act</I></B>. Neither the Company nor any of the Subsidiaries is or, after giving effect to the offering
and sale of the Offered Shares, will be an &#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company,&#148; as such terms are defined in the Investment Company Act of 1940, as amended (the &#147;<B>Investment
Company Act</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> <B><I>Operations</I></B>. The operations of the Company and its Subsidiaries are and have been
conducted at all times in compliance with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the
Company or its Subsidiaries are subject, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering
Laws</B>&#148;), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of
its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> <B><I><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements</I></B>. There are no transactions, arrangements and other relationships between and/or among the Company, and/or, to the knowledge of the Company, any of its affiliates and any
unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity (each, an &#147;<B>Off Balance Sheet Transaction</B>&#148;) that would reasonably be expected to affect materially the
Company&#146;s liquidity or the availability of or requirements for its capital resources, including those Off Balance Sheet Transactions described in the Commission&#146;s Statement about Management&#146;s Discussion and Analysis of Financial
Conditions and Results of Operations (Release Nos. <FONT STYLE="white-space:nowrap">33-8056;</FONT> <FONT STYLE="white-space:nowrap">34-45321;</FONT> <FONT STYLE="white-space:nowrap">FR-61),</FONT> required to be described in the Prospectus which
have not been described as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> <B><I>ERISA</I></B>. To the knowledge of the Company, each material employee benefit
plan, within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), that is maintained, administered or contributed to by the Company or any of its affiliates for employees or
former employees of the Company and any of its Subsidiaries has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Internal
Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;); no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred which would result in a material liability to the Company with
respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no
&#147;accumulated funding deficiency&#148; as defined in Section&nbsp;412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions)
exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B>
<B><I>Forward-Looking Statements</I></B>. No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) (a &#147;<B>Forward-Looking Statement</B>&#148;) contained in the
Registration Statement, the Time of Sale Prospectus and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. No such statement was made with the knowledge of an executive officer or
director of the Company that it was false or misleading. The Forward-Looking Statements incorporated by reference in the Registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statement, the Time of Sale Prospectus and the Prospectus (i)&nbsp;are within the coverage of the safe harbor for forward-looking statements set forth in Section&nbsp;27A of the Securities Act,
Rule 175(b) under the Securities Act or Rule <FONT STYLE="white-space:nowrap">3b-6</FONT> under the Exchange Act, as applicable, (ii)&nbsp;were made by the Company with a reasonable basis and in good faith and reflect the Company&#146;s good faith
commercially reasonable best estimate of the matters described therein, and (iii)&nbsp;have been prepared in accordance with Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> <B><I>Margin Rules</I></B>. Neither the issuance, sale and delivery of the Offered Shares nor the application of the proceeds
thereof by the Company as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of
Governors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> <B><I>Insurance</I></B>. The Company and each of its Subsidiaries carry, or are covered by, insurance in such
amounts and covering such risks as the Company and each of its Subsidiaries reasonably believe are adequate for the conduct of their properties and as is customary for companies engaged in similar businesses in similar industries. The Company has no
reason to believe that it or any of its Subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or
appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has been denied any insurance coverage which it has sought or
for which it has applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> <B><I>Communications</I></B>. The Company (i)&nbsp;has not alone engaged in communications with
potential investors in reliance on Rule 163B of the Securities Act other than Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Oral Communications, in each case with the prior consent of the Representatives with entities that are QIBs or IAIs and (ii)&nbsp;has not authorized anyone other than the Representatives to
engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Oral Communications and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communications; as
of the Applicable Time, each Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time,
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, if any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus
and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> <B><I>No Improper Practices</I></B>. (i)&nbsp;Neither the Company nor, to the Company&#146;s knowledge,
the Subsidiaries, nor to the Company&#146;s knowledge, any of their respective executive officers has, in the past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in
violation of law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any law or of the
character required to be disclosed in the Prospectus; (ii)&nbsp;no relationship, direct or indirect, exists between or among the Company or, to the Company&#146;s knowledge, any Subsidiary or any affiliate of any of them, on the one hand, and the
directors, officers and stockholders of the Company or, to the Company&#146;s knowledge, any Subsidiary, on the other hand, that is required by the Securities Act to be described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus that is not so described; (iii)&nbsp;no relationship, direct or indirect, exists between or among the Company or any Subsidiary or any affiliate of them, on the one hand, and the directors, officers, or stockholders of the Company or, to
the Company&#146;s knowledge, any Subsidiary, on the other hand, that is required by the rules of FINRA to be described in the Registration Statement, the Time of Sale Prospectus and the Prospectus that is not so described; (iv)&nbsp;except as
described in the Registration Statement, the Time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Sale Prospectus and the Prospectus, there are no material outstanding loans or advances or material guarantees of indebtedness by the Company or, to the Company&#146;s knowledge, any
Subsidiary to or for the benefit of any of their respective officers or directors or any of the members of the families of any of them; and (v)&nbsp;the Company has not offered, or caused any underwriter to offer, Common Stock to any person with the
intent to influence unlawfully (A)&nbsp;a customer or supplier of the Company or any Subsidiary to alter the customer&#146;s or supplier&#146;s level or type of business with the Company or any Subsidiary or (B)&nbsp;a trade journalist or
publication to write or publish favorable information about the Company or any Subsidiary or any of their respective products or services, and, (vi)&nbsp;neither the Company nor any Subsidiary nor, to the Company&#146;s knowledge, any employee or
agent of the Company or any Subsidiary has made any payment of funds of the Company or any Subsidiary or received or retained any funds in violation of any law, rule or regulation (including, without limitation, the Foreign Corrupt Practices Act of
1977), which payment, receipt or retention of funds is of a character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> <B><I>Sanctions</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company represents that, neither the Company nor any of its Subsidiaries (collectively, the &#147;<B>Entity</B>&#148;)
or, to such Entity&#146;s knowledge, any director, officer, employee, agent, affiliate or representative of the Entity, is a government, individual, or entity (in this paragraph (rr), &#147;<B>Person</B>&#148;) that is, or is owned or controlled by
a Person that is: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s
Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), nor </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation,
Crimea, Cuba, Iran, North Korea, Sudan and Syria). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Entity represents and covenants that it will not, directly or
indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of
such funding or facilitation, is the subject of Sanctions; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) in any other manner that will result in a violation of
Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Entity represents and covenants that, except as detailed in the Registration Statement, the Time of Sale Prospectus
and the Prospectus, for the past 5 years, it has not knowingly engaged in, is not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the
dealing or transaction is or was the subject of Sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> <B><I>Stock Transfer Taxes</I></B>. On the First Closing Date
(and, if applicable, on each Option Closing Date), all stock transfer or other taxes (other than income taxes) which are required to be paid in connection with the sale and transfer of the Offered Shares to be sold hereunder will be, or will have
been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> <B><I>Compliance with Laws</I></B>. The Company holds, and is operating in
compliance in all respects with, all material franchises, grants, authorizations, licenses, permits, easements, consents, certificates and orders of any governmental authority or self-regulatory body required for the conduct of its business except
where failure to do so would not, individually or in the aggregate, result in a Material Adverse Effect and all such material franchises, grants, authorizations, licenses, permits, easements, consents, certifications and orders are valid and in full
force and effect except where failure to be valid and in full force and effect would not, individually or in the aggregate, result in a Material Adverse Effect; the Company has not received notice of any revocation or modification of any such
material franchise, grant, authorization, license, permit, easement, consent, certification or order or has reason to believe that any such material franchise, grant, authorization, license, permit, easement, consent, certification or order will not
be renewed in the ordinary course; and the Company is in compliance in all material respects with all applicable federal, state, local and foreign laws, regulations, orders and decrees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> <B><I>Stock Exchange Listing</I></B>. The Common Stock is registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act
and are listed on the Nasdaq Global Market (&#147;<B>Nasdaq</B>&#148;) and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common
Stock from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance with all applicable listing requirements
of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> <B><I>Related-Party Transactions</I></B>. There are no business relationships or related-party transactions
involving the Company or any of its Subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been described as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> <B><I>FINRA Matters</I></B>. All of the information provided to the Underwriters or to counsel for the Underwriters by the
Company, its counsel, its officers and directors and, to the Company&#146;s knowledge, the holders of any securities (debt or equity) or options to acquire any securities of the Company, for submission to FINRA by the Underwriters in connection with
the offering of the Offered Shares is true, complete, correct in all material respects and compliant with FINRA&#146;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules
is true, complete and correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> <B><I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B>. The
Company has furnished to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit A</U> (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from each of the persons listed on <U>Exhibit B</U>. Such
<U>Exhibit B</U> lists under an appropriate caption the directors and officers (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) of the Company. If any additional persons shall become directors or officers
(as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) of the Company prior to the end of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined below), the Company shall cause each such person,
prior to or contemporaneously with their appointment or election as a director or officer (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) of the Company, to execute and deliver to the Representatives a <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> <B><I>Statistical and Market-Related Data</I></B>. All statistical,
demographic and market related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all
material respects. To the extent required, the Company has obtained the written consent to the use of such data from such sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> <B><I>Compliance with Occupational Laws</I></B>. The Company and each of its
Subsidiaries (i)&nbsp;is in compliance, in all material respects, with any and all applicable foreign, federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all governmental authorities (including
pursuant to the Occupational Health and Safety Act) relating to the protection of human health and safety in the workplace (&#147;<B>Occupational Laws</B>&#148;); (ii) has received all material permits, licenses or other approvals required of it
under applicable Occupational Laws to conduct its business as currently conducted; and (iii)&nbsp;is in compliance, in all material respects, with all terms and conditions of such permit, license or approval. No action, proceeding, revocation
proceeding, writ, injunction or claim is pending or, to the Company&#146;s knowledge, threatened against the Company or any of its Subsidiaries relating to Occupational Laws, and the Company does not have knowledge of any facts, circumstances or
developments relating to its operations or cost accounting practices that could reasonably be expected to form the basis for or give rise to such actions, suits, investigations or proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> <B><I>Cybersecurity</I></B>. The Company and its subsidiaries&#146; information technology assets and equipment, computers,
systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the
business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained
commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT
Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number,
<FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number;
(ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by GDPR; (iv)&nbsp;any information which would qualify as
&#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B><B>&#148;</B>); and
(v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation. To the
knowledge of the Company, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any
incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or
arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use,
access, misappropriation or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb)</B> <B><I>Compliance with Data Privacy Laws</I></B>. The Company and its subsidiaries
are, and to the knowledge of the Company at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries
have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are in compliance with, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679)
(collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material
respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company and its subsidiaries have at all
times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any
material respect. Neither the Company nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or
condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is
a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any
officer of the Company or any of its Subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by
the Company to each Underwriter as to the matters covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for making each of the
representations set forth in this Section&nbsp;1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely
upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Purchase, Sale and Delivery of the Offered Shares</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>The Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the several
Underwriters an aggregate of 3,906,250 Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not
jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule</U><B><U> </U></B><U>A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be
$30.08 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>The First Closing Date</I></B><B>.</B> Delivery of certificates for the Firm Shares to be purchased by
the Underwriters and payment therefor shall be made at the offices of Latham&nbsp;&amp; Watkins LLP, 12670 High Bluff Drive, San Diego, CA 92130 (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New York
City time, on June&nbsp;15, 2020, or such other time and date not later than 1:30&nbsp;p.m. New York City time, on June 29, 2020 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the
&#147;<B>First Closing Date</B>&#148;). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any
determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 585,937 Optional Shares
from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable on the Firm Shares but not payable on the
Optional Shares. The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30&nbsp;days from the date of this
Agreement. Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at which certificates for the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and
date are simultaneous with the First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of certificates for the Firm Shares and such Optional Shares). Any such time and date of delivery, if
subsequent to the First Closing Date, is called an &#147;<B>Option Closing Date</B>,&#148; and shall be determined by the Representatives and shall not be earlier than two or later than five full business days after delivery of such notice of
exercise. If any Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine)
that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Shares. The Representatives may
cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B><I>Public Offering of the Offered Shares</I></B><B>.</B> The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Payment for the Offered Shares</I></B><B>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Payment for the Offered Shares shall be made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer
of immediately available funds to the order of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) It is understood that the Representatives have been authorized, for
their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Goldman and
Jefferies, individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by
the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Delivery of the Offered Shares</I></B><B>.</B> The Company shall deliver, or cause to be delivered to the Representatives for
the accounts of the several Underwriters certificates for the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or
cause to be delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the case may
be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representatives so elect, delivery of the Offered Shares may be made by credit to the accounts designated by the
Representatives through The Depository Trust Company&#146;s full fast transfer or DWAC programs. If the Representatives so elect, the certificates for the Offered Shares shall be registered in such names and denominations as the Representatives
shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the
applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the
obligations of the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. Additional Covenants of the Company.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company further covenants and agrees with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus</I></B><B><I>.</I></B><I> </I>The Company shall
furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Shares is required by the
Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of the Time of Sale Prospectus, the Prospectus and
any supplements and amendments thereto or to the Registration Statement as you may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B><I>Representatives</I></B><B><I>&#146;</I></B><B><I> Review of Proposed Amendments and Supplements</I></B><B><I>.</I></B><I> </I>During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered
(whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any
proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any
report filed under the Exchange Act) without the Representatives&#146; prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). Prior to amending or supplementing any preliminary prospectus, the Time of Sale
Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of
filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives&#146; prior written consent (which
consent shall not be unreasonably withheld, conditioned or delayed). The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses</I></B><B><I>.</I></B><I> </I>The Company shall furnish to the Representatives for review, a
reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the
Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed).
The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a
prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time
through and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the
information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or
supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be;
<I>provided, however</I>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the
Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives&#146; prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Filing of Underwriter Free Writing Prospectuses.</I></B><I> </I>The Company shall not take any action that would result in an
Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been
required to file thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Amendments and Supplements to Time of Sale Prospectus</I></B><B><I>.</I></B><I> </I>If the
Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to
amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if,
in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) and Section&nbsp;3(c) hereof) promptly prepare, file
with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or
supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or
so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date of this Agreement, the Company shall
promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the time and date of any filing of any post-effective amendment to the
Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective amendment to the Registration
Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary
prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove,
suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.
If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with all applicable
provisions of Rule&nbsp;424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Amendments and Supplements to the Prospectus and Other Securities Act
Matters</I></B><B><I>.</I></B> If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser,
not misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b) and
Section&nbsp;3(c)) hereof to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so
amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether
physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives&#146;
consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b) or Section&nbsp;3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall cooperate with the Representatives and counsel for the Underwriters to
qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions designated by the
Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The Company shall not be required to qualify as a foreign
corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the
Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such
purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Use of Proceeds</I></B><B>.</B> The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in
the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Transfer Agent</I></B><B>.</B> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Earnings Statement</I></B><B>.</B> The Company will make generally available to its security holders and to the
Representatives as soon as reasonably practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that
will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder; <I>provided, however</I>, that the requirements of this Section&nbsp;3(k) shall be satisfied to the extent that such
earnings statement is available on EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will
comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus.
Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under
the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Listing</I></B><B>.</B> The Company will use its reasonable best efforts to
list, subject to notice of issuance, the Offered Shares on Nasdaq and to maintain the listing of the Shares on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>
<B><I>Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</I></B><B>.</B> If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from
the effective date of this Agreement, to the Representatives an &#147;<B>electronic Prospectus</B>&#148; to be used by the Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic
Prospectus</B>&#148; means a form of Time of Sale Prospectus, and any amendment or supplement thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may
be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Offered Shares; (ii)&nbsp;it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that
graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material,
as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus at
any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for <FONT STYLE="white-space:nowrap">on-line</FONT> time). The Company hereby confirms that it has included or will include in
the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it became effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall
transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of Sale Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Agreement Not
to Offer or Sell Additional Shares</I></B><B>.</B> During the period commencing on and including the date hereof and continuing through and including the 90th day following the date of the Prospectus (such period, as extended as described below,
being referred to herein as the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;), the Company will not, without the prior written consent of Goldman and Jefferies (which consent may be withheld in their sole discretion),
directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Common Stock or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in
Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(b)</FONT> under the Exchange Act) of any
Common Stock or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Common Stock or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Common Stock or Related Securities; (v)&nbsp;enter
into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Common Stock or Related Securities, regardless of whether any such transaction is to be settled in securities, in
cash or otherwise; (vi)&nbsp;announce the offering of any Common Stock or Related Securities; (vii)&nbsp;file any registration statement under the Securities Act in respect of any Common Stock or Related Securities (other than as contemplated by
this Agreement with respect to the Offered Shares); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention to
do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the transactions contemplated hereby, (B)&nbsp;issue Common Stock or options to purchase Common Stock, or issue Common Stock upon exercise of options, pursuant
to any stock option, stock bonus, restricted stock unit award or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, but only if the holders thereof (to the extent such holders are
the Company&#146;s executive officers and directors and have not already delivered a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) agree to restrictions on the resale of securities that are consistent with the form of <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter set forth in <U>Exhibit A</U> for the remainder of the <FONT STYLE="white-space:nowrap">90-day</FONT> restricted period, (C)&nbsp;issue Common Stock pursuant to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options, in each case outstanding on the date hereof and described in the Registration Statement,
the Time of Sale Prospectus and the Prospectus, but only if the holders thereof (to the extent such holders are the Company&#146;s executive officers and directors and have not already delivered a <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement) agree to restrictions on the resale of securities that are consistent with the form of <FONT STYLE="white-space:nowrap">lock-up</FONT> letter set forth in <U>Exhibit A</U> for the remainder of the
<FONT STYLE="white-space:nowrap">90-day</FONT> restricted period, (D)&nbsp;file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> to register Common Stock or Related Securities issuable pursuant to the terms of a stock
option, stock bonus or other stock plan or arrangement described in the Registration Statement, (E)&nbsp;issue Shares or Related Securities in connection with a commercial relationship (including joint ventures, marketing or distribution
arrangements, collaboration agreements or intellectual property license agreements) or acquisitions or licenses by the Company of the securities, business, property or other assets of one or more persons or entities or pursuant to any employee
benefit plans assumed by the Company in connection with any such acquisitions, as long as the aggregate number of shares of Common Stock issued or issuable does not exceed 5% of the number of shares of Common Stock outstanding immediately after the
issuance and sale of the Shares; <I>provided that</I>, in the case of clause (E), each recipient of any such Shares or Related Securities agrees to restrictions on the resale of securities that are consistent with the form of <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter set forth in <U>Exhibit A</U> for the remainder of the <FONT STYLE="white-space:nowrap">90-day</FONT> restricted period. For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean
any options or warrants or other rights to acquire Common Stock or any securities exchangeable or exercisable for or convertible into Common Stock, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible
into, Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>Future Reports to the </I></B><B><I>Representatives</I></B><B><I>.</I></B><I> </I>During the period
of three years hereafter, the Company will furnish to the Representatives, c/o Goldman, at 200 West Street, New York, New York 10282, Attention: Registration Department and c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention:
Global Head of Syndicate: (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income,
stockholders&#146;<I> </I>equity and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy
statement, Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the
Company with the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I>
that the requirements of this Section&nbsp;3(p) shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>Investment Limitation</I></B><B>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from
its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>No Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>. </B>The Company will not take, and
will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares,
whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B><B><I>s</I></B><B>.</B> During the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related
Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will direct the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the
duration of the periods contemplated in such agreements, including, without limitation, <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered into by the Company&#146;s officers and directors pursuant to Section&nbsp;6(j)
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Company to Provide Interim Financial Statements</I></B><B>.</B> Prior to the First Closing Date and each
applicable Option Closing Date, the Company will furnish the Underwriters, as soon as practicable after they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period
subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus; <I>provided, however</I>, that the requirements of this Section&nbsp;3(t) shall be satisfied to the extent that such
reports, statement, communication, financial statement or other documents are available on EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>Internal
Controls.</I></B> The Company and its subsidiaries will maintain such controls and other procedures, including without limitation those required by Sections 302 and 906 of the Sarbanes-Oxley Act and the applicable regulations thereunder, that are
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s
rules and forms, including without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the
Company&#146;s management, including its principal executive officer and its principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, to ensure that material
information relating to the Company, including its subsidiaries, is made known to them by others within those entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>
<B><I>Sarbanes-Oxley.</I></B> The Company and its subsidiaries will comply with all applicable provisions of the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B><I>Amendments and Supplements to Permitted
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications</I></B>. If at any time following the distribution of any Permitted
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, there occurred or occurs an event or development as a result of which such Permitted <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B><I>Communications</I></B>. The Company (i)&nbsp;has not alone engaged in communications with potential investors in reliance on
Rule 163B of the Securities Act other than Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Oral Communications, in each case with the prior consent of the Representatives with entities that are QIBs or IAIs and (ii)&nbsp;has not authorized
anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Oral Communications and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communications; as of the Applicable Time, each Permitted <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, include an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, if any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary
Prospectus and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, on behalf of the several Underwriters, may, in their sole discretion,
waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Payment of Expenses</B><B>.</B> The Company agrees to pay all costs, fees and expenses incurred in
connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares (including all
printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Shares to the
Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf
of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication and all amendments and supplements thereto,
and this Agreement, (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any
part of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum and a
&#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, such fees and expenses not to exceed $5,000, (vii)&nbsp;the costs, fees and expenses incurred by the
Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares, including any related filing fees and the
legal fees of, and disbursements by, counsel to the Underwriters, such legal fees not to exceed $10,000, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148;, any Permitted <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Oral Communication undertaken in
connection with the offering of the Offered Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees
and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and
one half of the cost of any aircraft chartered in connection with the road show, <I>provided, however</I>, that the prior written approval of the Company was obtained prior to the chartering of any such aircraft, (ix)&nbsp;the fees and expenses
associated with listing the Offered Shares on Nasdaq, and (x)&nbsp;all other fees, costs and expenses of the nature referred to in Item 14 of Part&nbsp;II of the Registration Statement. Except as provided in this Section&nbsp;4 or in Section&nbsp;7,
Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <B>Covenant of the Underwriters</B><B>.</B> Each Underwriter severally and not jointly covenants with the
Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would
not, but for such actions, be required to be filed by the Company under Rule 433(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B> <B>Conditions
of the Obligations of the Underwriters</B><B>.</B> The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares,
each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the
following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have
received from Deloitte&nbsp;&amp; Touche LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing
statements and information of the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited
and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Compliance with Registration Requirements; No Stop Order; No Objection from </I></B><B><I>FINRA</I></B><B><I>. </I></B>For
the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information previously omitted from the
Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a
<FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement containing the information previously omitted from the Registration Statement pursuant to Rule 430B, and such post-effective amendment shall have become
effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the
underwriting terms and arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the period
from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization&#148; as that term is used in <FONT STYLE="white-space:nowrap">Rule&nbsp;15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Opinion of Counsel for the Company</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the
Representatives shall have received the opinion and negative assurance letter of Paul Hastings LLP, counsel for the Company, in form and substance reasonably satisfactory to the Underwriters, dated as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Opinion of Intellectual Property Counsel for the Company.</I></B><I> </I>On each of the First Closing Date and each Option
Closing Date, the Representatives shall have received the opinion of Morrison&nbsp;&amp; Foerster LLP, counsel for the Company with respect to certain intellectual property matters, in form and substance reasonably satisfactory to the Underwriters,
dated as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Opinion of Counsel for the Underwriters</I></B><B>.</B> On each of the
First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters in connection with the offer and sale of the Offered
Shares, in form and substance satisfactory to the Underwriters, dated as of such date.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>
<B><I>Officers</I></B><B><I>&#146;</I></B><B><I> Certificate</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President
of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further to the effect that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) for the period from and including the date of this Agreement through and including such date, there has not occurred any
Material Adverse Change; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the representations, warranties and covenants of the Company set forth in Section&nbsp;1 of
this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed
or satisfied hereunder at or prior to such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Chief Financial Officer&#146;s Certificate</I></B>. On each of the date
hereof, the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Financial Officer of the Company, dated as of such date, with respect to certain financial data contained in the
Time of Sale Prospectus and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Bring-down Comfort Letter</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the Representatives
shall have received from Deloitte&nbsp;&amp; Touche LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance reasonably satisfactory to the Representatives, which letter shall: (i)&nbsp;reaffirm
the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than two business days prior to the First Closing Date or the
applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B><I>.</I></B> On or prior to the date hereof, the Company
shall have furnished to the Representatives an agreement in the form of <U>Exhibit A</U> hereto from each of the persons listed on <U>Exhibit B</U> hereto, and each such agreement shall be in full force and effect on each of the First Closing Date
and each Option Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Rule</I></B><B><I></I></B><B><I>&nbsp;462(b) Registration Statement</I></B>. In the event
that a Rule&nbsp;462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule&nbsp;462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall
have become effective automatically upon such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Additional Documents</I></B>. On or before each of the First
Closing Date and each Option Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance
and sale of the Offered Shares as contemplated herein, or in order to evidence the accuracy of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and
sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall
be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Reimbursement of Underwriters</B><B>&#146;</B><B> Expenses</B>. If this Agreement is terminated by the
Representatives pursuant to Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the
Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves),
severally, upon demand for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the
proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, actual, reasonable and documented fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Effectiveness of this Agreement</B>. This Agreement shall become effective upon&nbsp;the execution and
delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>Indemnification</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which
such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign
jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included
in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Material, any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material
fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or
relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i)&nbsp;or (ii)
above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent and controlling person for any and all actual, reasonable and documented expenses (including the reasonable fees and disbursements of counsel) as such reasonable expenses are incurred by
such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided,
however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or
alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of
Sale Prospectus, any such free writing prospectus, any Marketing Material, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communication or the Prospectus (or any amendment or supplement
thereto), it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the
Company may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each Underwriter agrees,
severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or
the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state
statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or
actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary
prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act, any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements,
in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration
Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communication or the Prospectus (or any
such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director,
officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending,
settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration
Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Written Communication or the Prospectus (or any amendment or supplement to the foregoing) is the concession figure appearing in the fifth<B> </B>paragraph under the caption
&#147;Underwriting&#148; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement set forth in this Section&nbsp;9(b) shall be in addition to any liabilities that each Underwriter may otherwise have. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Notifications and Other Indemnification Procedures</I></B><B>.</B> Promptly
after receipt by an indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the
indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying
party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is
brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other
indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such
indemnified party; <I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the
positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available
to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon
receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election to so assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to
such indemnified party under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in
accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the
indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in
Section&nbsp;9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above) or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to
represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying
party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Settlements</I></B><B>.</B> The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or
expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such
indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and
indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such
action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Contribution</B>. If the indemnification provided
for in Section&nbsp;9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party
shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the
relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted
by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in
connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the
Underwriters, on the other hand, in connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this
Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial
public offering price of the Offered Shares as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or
alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party
as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any legal or other fees or expenses reasonably incurred by such party in
connection with investigating or defending any action or claim. The provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10;
<I>provided, however,</I> that no additional notice shall be required with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were
determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the
underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in
proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person,
if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the
Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Default of One or More of the Several
Underwriters</B><I>.</I> If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the
aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may
make arrangements satisfactory to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and
not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on <U>Schedule</U><B><U> </U></B><U>A</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the
Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase
Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the
Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7,
Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option
Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to include any person substituted for a defaulting
Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>Termination of this Agreement</B><I>.</I> Prior to the purchase of the Firm Shares by the
Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or limited
by the Commission or by Nasdaq or trading in securities generally on either Nasdaq or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock
exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York, Delaware or California authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or
any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or
economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce
contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other
calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to
this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section&nbsp;4 or
Section&nbsp;7&nbsp;hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B> <B>No Advisory or Fiduciary Relationship. </B>The
Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an <FONT
STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process leading to
such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an
advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters)
and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad
range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has
consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B> <B>Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities,
agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made
by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for
the Offered Shares sold hereunder and any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Notices</B>. All
communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Representatives:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Registration
Department</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT
STYLE="white-space:nowrap">619-4437</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12670 High Bluff
Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (858) <FONT
STYLE="white-space:nowrap">523-5450</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Cheston Larson</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Tower Place</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, California 94080</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (415) <FONT
STYLE="white-space:nowrap">287-2459</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Peter Maag, Ph.D.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paul Hastings LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1117 S. California Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, California 94304</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (650) <FONT
STYLE="white-space:nowrap">320-1904</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Jeffrey T. Hartlin</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B> <B>Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties
hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each
case their respective successors, and personal representatives, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such from any of the
Underwriters merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B> <B>Partial Unenforceability</B>. The invalidity or
unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason
determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18</B>. Recognition of the U.S. Special Resolution Regimes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event
that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 382.2(b); (C) &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#147;<B>U.S. Special Resolution
Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Governing Law Provisions</B><I>.</I> This Agreement
shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the
transactions contemplated hereby (&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in
each case located in the Borough of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the
enforcement of a judgment of any such court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any
process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any
objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in
any such court has been brought in an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20.</B><B>General Provisions</B><B>.</B> This
Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement
may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or
implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities
Act and the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CAREDX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter Maag</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Peter Maag, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chairman and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GOLDMAN SACHS&nbsp;&amp; CO. LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JEFFERIES LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting individually and as Representatives
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the attached
<U>Schedule A</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GOLDMAN SACHS&nbsp;&amp; CO. LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Raffael Fiumara</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Raffael Fiumara</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Vice President</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Real Leclerc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Real Leclerc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,660,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,660,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BTIG, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig-Hallum Capital Group LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,906,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[None.] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[None.] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule D </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Subsidiaries </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx International
AB </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx AB </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx Lab Solutions, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx Transplant Management, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx GmbH </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx Pty Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XynManagement, Inc. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Attached] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10282 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RE:&nbsp;&nbsp;&nbsp;&nbsp;CareDx, Inc. (the &#147;<B>Company</B>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned is
an owner of shares of common stock, par value $0.001 per share, of the Company (&#147;<B>Shares</B>&#148;) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the
&#147;<B>Offering</B>&#148;) for which Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC (the &#147;<B>Representatives</B>&#148;) will act as the representatives of the underwriters. The undersigned recognizes that the Offering will benefit each of
the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in
entering into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other underwriting arrangements with the Company with respect to the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this letter agreement.
Those definitions are a part of this letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not (and will cause any Family Member not to), without the
prior written consent of each of the Representatives, which may withhold their consent in their sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or
beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned or such Family Member, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Swap, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the
offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in each
case as contemplated by the Underwriting Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may transfer Shares (i)&nbsp;as a bona fide
gift or gifts, (ii)&nbsp;to any trust for the direct or indirect benefit of the undersigned or a Family Member, (iii)&nbsp;if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (1)&nbsp;to
another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or (2)&nbsp;as
distributions of Shares or Related Securities to limited partners, limited liability company members or stockholders of the undersigned, (iv)&nbsp;if the undersigned is a trust, to the beneficiary of such trust, (v)&nbsp;by testate succession or
intestate succession, (vi)&nbsp;to the Company pursuant to any contractual arrangement that provides for the repurchase of the undersigned&#146;s Shares or Related Securities by the Company or in connection with the termination of the
undersigned&#146;s employment or other service relationship with the Company, or (vii)&nbsp;to the Company as forfeitures to satisfy tax withholding obligations of the undersigned in connection with the vesting or exercise of equity awards pursuant
to the Company&#146;s equity incentive plan or outstanding warrants; <I>provided</I>, <I>however</I>, that in any such case, it shall be a condition to such transfer that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such transfer shall not involve a disposition for value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each transferee executes and delivers to the Representatives an agreement in form and substance satisfactory to
the Representatives stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage
in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto), and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or
filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection with such transfer (other than, in
connection with a repurchase of Shares or Related Securities by the Company pursuant to clause (vi)&nbsp;or a forfeiture to satisfy tax withholding obligations pursuant to clause (vii), a Form 4 or Form 5 required to be filed under the Exchange Act
if the undersigned is subject to Section&nbsp;16 reporting with respect to the Company under the Exchange Act, provided, however, that if such Form 4 or Form 5 is filed during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, such Form 4
or Form 5 shall indicate by footnote disclosure or otherwise that such Form 4 or Form 5 relates to a repurchase of Shares or Related Securities by the Company in connection with the termination of the undersigned&#146;s employment with the Company
or a forfeiture to satisfy tax withholding obligations, as applicable, and that any Shares or Related Securities subject to this letter agreement that continue to be held by the undersigned remain subject to the terms of this letter agreement).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the foregoing restrictions shall not apply to (i)&nbsp;the exercise, conversion or exchange (including by
means of a cashless exercise) of stock options granted pursuant to the Company&#146;s equity incentive plans or any warrants, rights or other convertible securities outstanding on the date hereof; provided that such restrictions shall apply to any
of the Shares issued upon such exercise, conversion or exchange, (ii)&nbsp;the establishment of any contract, instruction or plan (a &#147;<B>Plan</B>&#148;) that satisfies all of the requirements of Rule
<FONT STYLE="white-space:nowrap">10b5-1(c)(1)(i)(B)</FONT> under the Exchange Act; provided that no sales of Shares shall be made pursuant to such a Plan prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and such
a Plan may only be established if no public announcement of the establishment or existence thereof and no filing with the SEC or other regulatory authority in respect thereof or transactions thereunder or contemplated thereby, by the undersigned,
the Company or any other person, shall be required, and no such announcement or filing is made voluntarily, by the undersigned, the Company or any other person, prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period,
(iii)&nbsp;transfers of Shares pursuant to a Plan that satisfies all of the requirements of Rule </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">10b5-1</FONT> and that is in effect as of the date of the Underwriting Agreement (and any related filings in connection with such sale or disposition that are
required under the Exchange Act; provided that any such filings shall indicate by footnote disclosure or otherwise (1)&nbsp;that such sale or disposition was made in connection with a Plan and (2)&nbsp;the date such Plan was entered into); (iv)
transactions related to Shares or Related Securities acquired in open market transactions after the completion of the Offering or to Shares acquired in the Offering; provided that no filing under Section&nbsp;16(a) of the Exchange Act shall be
required or shall be voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period in connection with subsequent sales of Shares or Related Securities acquired in such open market transactions; or (v)&nbsp;transfers of shares of
Shares or Related Securities pursuant to any bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Company&#146;s capital stock involving a change of control of the Company which is
approved by the Company&#146;s Board of Directors (including, without limitation, the entering into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree to transfer, sell,
tender or otherwise dispose of common stock or other such securities in connection with such transaction, or vote any common stock or other such securities in favor of any such transaction); provided, that in the event such tender offer, merger,
consolidation or other such transaction is not completed, the Shares or Related Securities shall remain subject to the terms of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar
against the transfer of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the
offer and sale of any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any
action designed to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family
Member not to take, directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all
depends on market conditions and other factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter
agreement. This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Company notifies the Representatives in writing that it does not intend to proceed with the Offering, (ii)&nbsp;the
Underwriting Agreement is not executed before June&nbsp;30, 2020 (provided that the Company may by written notice to the undersigned on or before June&nbsp;30, 2020, extend such date for a period of up to an additional three months), (iii) the
purchase of Firm Shares (as defined in the Underwriting Agreement) does not occur by June&nbsp;30, 2020 (provided that the Company may by written notice to the undersigned on or before June&nbsp;30, 2020, extend such date for a period of up to an
additional three months) or (iv)&nbsp;the Underwriting Agreement (other than the provisions thereof that survive </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination) terminates or is terminated prior to payment for and delivery of the Firm Shares, then in each case, this letter agreement shall automatically, and without any action on the part of
any other party, terminate and be of no further force and effect, and the undersigned shall automatically be released from the obligations under this letter agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Printed Name of Person Signing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><I>(Indicate capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Call Equivalent Position</B>&#148;<B> </B>shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Exchange Act</B>&#148;<B> </B>shall mean the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Family Member</B>&#148; shall mean the spouse of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member
may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth
in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; shall mean the period beginning on the
date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus (as defined in the Underwriting Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any
securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">sell, offer to sell, contract to sell or lend, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call Equivalent Position </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">pledge, hypothecate or grant any security interest in, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">in any other way transfer or dispose of, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or indirectly. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole
or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors and Officers </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Signing <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">George W. Bickerstaff, III </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fred E. Cohen, M.D., D. Phil </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grace E. Col&oacute;n, Ph.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christine M. Cournoyer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael D. Goldberg </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William A. Hagstrom </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ralph Snyderman, M.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Officers: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Maag, Ph.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reginald Seeto, MBBS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Bell </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sasha King </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d923446dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g923446snap0001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;11, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Tower Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to CareDx, Inc.,
a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the preparation and filing with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) pursuant to Rule 424(b) of the rules and regulations
of the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), of a prospectus supplement, dated June&nbsp;10, 2020 (the &#147;<B><I>Prospectus Supplement</I></B>&#148;), to the Company&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-239049)</FONT> originally filed with the Commission under the Act on June&nbsp;9, 2020 (the &#147;<B><I>Registration Statement</I></B>&#148;), and the
related prospectus, dated June&nbsp;9, 2020, included in the Registration Statement at the time it originally became effective (the &#147;<B><I>Base Prospectus</I></B>&#148; and, together with the Prospectus Supplement, the
&#147;<B><I>Prospectus</I></B>&#148;), relating to the offering by the Company of up to 3,906,250 shares (the &#147;<B><I>Shares</I></B>&#148;) of the Company&#146;s common stock, par value $0.001 per share (&#147;<B><I>Common Stock</I></B>&#148;),
and up to an additional 585,937 Shares subject to an over-allotment option granted to the underwriters of the offering. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and
Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC, as the representatives of such underwriters, dated as of June&nbsp;10, 2020 (the &#147;<B><I>Underwriting Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus, the Underwriting Agreement, the Company&#146;s
Amended and Restated Certificate of Incorporation, as amended, and the Company&#146;s Amended and Restated Bylaws, as amended, each as currently in effect, and the originals or copies certified to our satisfaction of such records, documents,
certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have
not independently verified such matters. We have assumed the genuineness and authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is
expressed solely with respect to the federal laws of the United States and the General Corporation Law of the State of Delaware. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating
to securities, or to the sale or issuance thereof. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our
attention and which may alter, affect or modify the opinion expressed herein. We express no opinion as to whether the laws of any particular jurisdiction other than those identified above are applicable to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold against payment therefor in accordance
with the Underwriting Agreement, will be validly issued, fully paid and nonassessable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g923446snap0002.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g923446snap0003.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 11, 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus included in the Registration Statement and to the filing
of this opinion as an exhibit to a Current Report of the Company on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Paul Hastings LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d923446dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g923446g0611130034338.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CareDx Announces Pricing of Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOUTH SAN FRANCISCO, Calif., June&nbsp;10, 2020 (GLOBE NEWSWIRE) &#151;&nbsp;CareDx, Inc.&nbsp;(Nasdaq: CDNA), a leading precision medicine company focused on
the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the pricing of an underwritten public offering of 3,906,250 shares of its common
stock at a public offering price of $32.00 per share. The gross proceeds to CareDx from this offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $125,000,000. In addition, CareDx has granted
the underwriters a 30 day option to purchase up to 585,937 additional shares of its common stock offered in the public offering on the same terms and conditions. The offering is expected to close on or about June&nbsp;15, 2020, subject to the
satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx intends to use the net proceeds from this offering for working capital and general corporate
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. BTIG, LLC and Craig-Hallum
Capital Group are acting as <FONT STYLE="white-space:nowrap">co-managers</FONT> for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering will be made pursuant to a shelf
registration statement on Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-239049)</FONT> previously filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on June, 9, 2020,
which became effective immediately upon filing pursuant to SEC rules. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the
offering have been filed with the SEC and are available on the SEC&#146;s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, copies of the final prospectus supplement and the
accompanying prospectus relating to the offering may be obtained from Goldman Sachs&nbsp;&amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by <FONT STYLE="white-space:nowrap">e-mail</FONT> at <FONT
STYLE="white-space:nowrap">prospectus-ny@ny.email.gs.com</FONT> or by telephone at (866) <FONT STYLE="white-space:nowrap">471-2526;</FONT> or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York,
NY 10022, by <FONT STYLE="white-space:nowrap">e-mail</FONT> at prospectus_department@jefferies.com or by telephone at (877) <FONT STYLE="white-space:nowrap">821-7388.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;CareDx </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and
commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the <FONT STYLE="white-space:nowrap">pre-</FONT>
and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended,
including statements relating to the underwritten public offering and the expected closing date thereof and the amount of proceeds expected from the offering. These forward-looking statements are based upon information that is currently available to
CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with market conditions and the satisfaction of customary closing conditions related to the
proposed public offering, as well as general economic and market factors, among others&nbsp;discussed in CareDx&#146;s filings with the SEC, including the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year
ended&nbsp;December 31, 2019&nbsp;filed by CareDx with the&nbsp;SEC&nbsp;on&nbsp;February 28, 2020 and the periodic reports that CareDx has subsequently filed with the SEC, and the preliminary prospectus supplement related to the proposed offering
filed with the SEC on or about the date hereof. Any of these may cause CareDx&#146;s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx&#146;s forward-looking statements. CareDx
expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greg Chodaczek </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">347-620-7010</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investor@caredx.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cdna-20200610.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-4 Build:20200505.2 -->
<!-- Creation date: 6/11/2020 11:54:56 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:cdna="http://www.caredxinc.com/20200610"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.caredxinc.com/20200610"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdna-20200610_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdna-20200610_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cdna-20200610_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-4 Build:20200505.2 -->
<!-- Creation date: 6/11/2020 11:54:56 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cdna-20200610_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-4 Build:20200505.2 -->
<!-- Creation date: 6/11/2020 11:54:56 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cdna-20200610.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g923446g0611130034338.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923446g0611130034338.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% .<# 2(  A$! Q$!_\0
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G((Q)(K0%RC[58X<Y888$?IVHHH UHHQ#"D2DD(H4$]>**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g923446snap0001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923446snap0001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M"^FZG<I&D]S")'6,$*"?3))_6G!\T4V1B*:I590CLC7JC * "@ H * "@ H
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M6&#M(50?QVY_&IH)J&IMFE2,Z]H]%8M?%O\ Y)CJ_P#VQ_\ 1R55;X&1EO\
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M0%7Q3XDU'P[XATUY%4:+-A9GV9*MDYY^F#^!H V/M7AW4H/.,EC/&1]YMIH
MX+3(K(_%R(^'L"R2,F<Q?<SM.?PSM_&F(]6I#.(^*O\ R)O_ &\)_6@#K-+_
M .019?\ 7!/_ $$4 6Z /.O"?_)4O$OT;_T(4P/0W_U;?2D!YY\(O^03J?\
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M_/% '/?\*X\)_P#0)_\ )B7_ .*H V=)T+3-"@:'3;18$8Y."6)_$DF@#1H
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A % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g923446snap0002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923446snap0002.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M:@"?5=2GL9;:*-%42ABTK(SA,8P-J\\YZ].* +ME<&ZLHIFV!F7G8V1GO@T
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M+C:%19$C+$ S(?ES_LD$@_04 59- U*,1-;W>YX8EE&YR!)< C)/^R1D8]Z
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MEMY4BB\PGRW8(%/'NI/XT :FF6$ME<7)9\Q2"/:NXG!"X8_C0!I4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
A 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g923446snap0003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923446snap0003.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0 4 8NGWOAO2K*.RL+W3[>VCSLC2=0!DY/?U)I)**LBYSE.7-)W9:_M[1_\
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M %\O_P"@B@"7X@?\B-J?T3_T-: ,E!_P@FI1RJ&.@:@PWCK]EE/?_=/]/;D
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M0!9TKPQ*FL?VYK%TMUJ@&$,2[8XEP1@#OU/6@#I: "@ H * "@ H * "@ H
7* "@ H * "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6628329136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001217234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 10,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CAREDX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3316839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Tower Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">287-2300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDNA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MH:<,HA; ^F5B/$U#!U?  B-,+G\7T*S$4OT36SK SLDIVS4UCF,];DINWD'
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M+=1O/" PSB%4&R_BD72FMW>3>PZ[U_J!L7?[ZE32CQKCQRU_ %!+ P04
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ML)\)VV$]=N'?(*EA.N_6_VATF<N@7?S-R$=*[4%?#?_)\@M02P$"% ,4
M" !&@,M0'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    " !&@,M0)^B'#H(   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $: RU :.MA5[0   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( $: RU"97)PC$ 8  )PG   3              "  ;4"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ 1H#+4#B?:PB< @  DPL  !@
M         ( !]@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( $: RU!@H7I(30(  .P%   4              "  <@+  !X;"]S:&%R
M9613=')I;F=S+GAM;%!+ 0(4 Q0    ( $: RU"ZH3F*UP$  #(&   -
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64$L%!@     *  H @ (    4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-20-166621-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-166621-xbrl.zip
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M"!K$+;1NI=FY?[SEPQ<RHV8)S>//P<*9:WMNIXN'$B.B/*;YTL&FA[MR>*P
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MK2%B%EZS$11'0JW+'RCAM>9^S6K^$?+,4^5X1#W)CAJYSA<&<YV/E5\4'7_
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MSRM$IUG7-7<S>8>M9GSSFG$E&/H*/(^HCIL@SA 0.FT>%WR+&I)GZB+?*\?
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MU$F8&@]8)XCUBR0&@'P8HN4?VRWH-M,7T)+M1C$6B<NR!7 'J(.2%76X!R
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MFMX3_.M;]U<[1Q:,=,Z"6S(>N=5<KB9Y-MW]MKS'2]J_9'2@0//"&4!AZ":
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M H(SN4BR/)F Y.QS@%L:"[ZRP/@>6M9IW=!+U2VNNFHW.OKQ>%#1W@$9+59
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M4V[^V&IRT<F*#"^<T +[WB+M]6O_H!T4<GREWH6F:7(M1:L]V+4ZBPRW"""
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MZ!AHLZM8[.2;KAQUD%M?L-%.--0Z^ ;D(4+JLTD-0MW45O1-%*.S;"B"4O!
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M,]0 L>7R-0[6\C#:@H+D1)%I):1S:5G '_<]-P#/*/.<(W \==*B5GIV#RD
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M?^-?+D@GX:VJ_5'$*ZQIU]N1;Q=!G64H)JXJW';VO?LETBUYX9>[DV:^)=8
M\B*WVIQ;O_ AI;+; UB,@]\3YM@DF]2%QH-XJNY%IYU@JX*CQ5V 7[O%8<>L
M1SZ[AQ^I2S>/[1;_#A&.JTWDF^K#AY7B@V2)Q,4J;=[$?/,VZ]:&?'31'6$7
MUI_/ATM3PR_WD'OVDV3>_F9O;!O8W6S:6>9BOAT9]JGEY?7*#2O$78(7ZQ89
MQX>H("9AFC%^QSZ%A?JRI.0Q-2K0&DVJ.9 @>JG50$?WCY\,\.N8:H,K;_'-
M2=,(6WQ\A;>^07Z^IZW$6  ?=7E)KE,S]6E]MXJ^[8!:+F[SK],G9/2=GIS6
MFK)L;_ *S TRBPGD0A@POQ5][R+[B$BYO+]B)_(P$ QHB]N:V+XG>D?=CX:A
M+93Y96(Z:D.6A36JKQP([Y5(R'J'L,]-R(6>#:0%_@IGYW<I67S:6G4/@3CQ
M!M8'DMQTK-K7:N,"W+B^_[_M?5ES&T>6[CLC^!\J/-,38$2)35*[U:T(BI)L
M]I4LABBW9^+&?2@"!;(L  57 :0PO_[FV3)/9F5AX0)2-OJA+9) 52XG3Y[U
M^Q!,"(O,>DR[<T[Y(2OHK4@!O:)'[9MS9KC:I;N]5=X+(#$Y78H> E']P2<(
M;]=7-FAVOV8:L8^EMH12;X(J9T]OB\>(8E:*GV0)1,/O,N7Q=)/RN"5#YTNL
MXLYCKL0#"]%.<[C](/(PF\FY;?9N0Q(;X*PUPQ.';E&R?>(?J;W&_ZA*ZK#Z
M%$.^(RD>I8YY%WWBI$A1Z;?<W'I\>0WKD>.&DCNF_S!MRJ[8E2?93'3L.[+3
MZ]8B&%>>/,YF"8$TUQ 9[@L8#9OZ")E!?B$VV$9@AO0><.)8PXK;(*7@8L2>
ML;C5<FZDU15#0KY;C;SHJ3B_5QVNX-5C-0^JW8#9QPHAP>Z!S55EER1 9M5V
M4ET*")F2QB+R2^9"HWJE'JE7T@:E+.X2A*KZ5'W;1J;-W38< _9SO+FBL09S
M:CXDN.B?4=? /G>:0422L=33:Q19JLDA/'6)H]"#P!UHE=CH&E *BF]5V=B4
M:S2A O6B&(]EKV-(DRV)'B4SL801%$E@A0(D8+H7>0\BUJFX$PP[3VO1Q6(9
MJ []!BTB]<X"2B[_*F8C<U5B82BS3@5DC#GQ'#Z(KUU39Q.U<8A%#=WUV4M4
MRP(A3C]>Z)%S,-88N%N]),1M4\@!(.Q4P0LR#R$1XUB/\IGP<\_1FN&M%.-;
M:8HI ]%S3Y.4_L&/CD$ ?HJ1""Q"8M_!9:&LJ%%LF:OV;H->=\K"I2J6HB6@
MT];*2  =/D!<D*$XH86[&-B/Q%>.I]/+W$EB62%.I]5E/N/^$;  <F,#F*],
MAR0:VUOT!4N= %)F3AM]PP'5Q02&E)$8(=YF2K7[*C0''$]K2A'6+Y;2*_6?
M3].]O;U4XU"@7[/PYI9"ZT52U\N)?X\G5E0-U%>\Q-I@EZE4N^(^G@B/CK#9
M&Y$K(,G$45M7(39/Z?K"J0T"BFW06]4Q%2=E>VN0GV=\71&9"K[A;%K54@LW
M2RWC1V3<O#_J,<'&[.^YG6ELS;PKTDM>60 OC4Q7)UP@1-):E1D46I973DQG
M]QI.D J]>XG4V0A4/FHU3S72RUPYBE<NV8W+ZKKL%IGDJ4-+@GM/&0=1I784
MWI_=O(6/+7O3KCS$?BNI!\:>)7EB"$4^]W2!:1GCIAU(T614.:7"QLU%<N_P
M92\(?6)2]Q)3PKXU8!3;I3D[,(I!V3NGJRFT?0-%+@VK;.1)W5;83635,$-^
M\8RXI!O<.^U;PHF3^6=%U:VR/B'52>'8_.FGRU3F^'!E+6N27$%TYHQ#+6-=
MEL7#4>A#5$['PTT5! ZZJZ%B!VA*7V@$'SARB5N08-)[G6_*IF$VH)S,T#95
M9<1YBH27SA@TRWALK-ID_PE\Z,1,AQYZ?#S?1-Z%"@> &L5*,>[#Q0L@K&UZ
MPG7$WB^?IP$/W$N"[=.\ 7LV#-:XFJE4"AQ>NMQ41LN[3[Q%]R\*FEUA"?0>
M7#C@J0T'''%L0W9$+X47%W@'AKKZJ\1G!G3XX*K#COO!3,5+Y.BX[BV^$N=0
M([D&"'U.!(K0U=2T<O?I(DYA8^WT=N9PPZ[L!%G[32\(SD%A?L)LD(*1T#T(
MYQ3[YMF<"VBE+"S]')I9G,F-"TQN69J>*6D2L&7NQC6*1@5Y%LG8%[P </&Q
MZJCYU5A04,6.-(06VOW9S'9^-HD?K&YA5$MNNX_7PZ9QP+2QAP*: HF'V>)H
MJ:RKP50,7%"WAVC$W5GL"A0O@-O7B]R" VB/S#:MZ>Y]7^%9%)M8,H"N3_N7
MV * 5X,0I!-("U&7HRS*=XS2]&P3U+]V'\."H\ "U78>8B)E4?"Y G!^W!Y[
M:.U5XT* T; R=Z25&B5^>\N57&4.T%<CQK>+X[.[*@')@A(0.-#)!X3G:-3Q
M?VK 5*71?#VI'LC:P[9QJRJ&@M[F@Q(L5#I]_Y4-QZ^2+Z6YIO+DPX<3/Q@K
M :9X#%;TK"K+9U"1'GGZH<[I]2JL](W[TD:#82<61>/.*"&KJ:^6@D-WB 2J
M;[[F'(/+=K+BF\S&D ;J09BR "PN*14#(%8[50E8,X8M[Q#-56C@S'BFWG04
MK%:W6U(QZZ1486$SA$/H6T"<2P"PR:J>D8UREXW: TV-"$%^B*1-!T!X--J)
M7T[<!T%NGVN+B+<I<%@92MK=!ZZ=$9Y+[# O[BP)['NJOSH+NVR"KF(WX<^J
M\>)5@@W+Y3CY5"%_F/GQ$][Q\$D\9WY3)\;  H 3^Y'W)1,E<<<)?A]OZ$4$
M:A3*:H,*7]:N 1D+E+FUJO0@FL]+6[7]C_.VLTV5\J_@,L/=O-'N=HJ=2(,_
M%C*1U>UG1Z*>1<=?4'TZC-ZY+(A)08I#)=0.7'[13%#$4=E[T^JF[,BY$Y"
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M!U[]<2=O&RP:;EC2+[7_ML PE<(F1#!DD&46R$GV#7=3>@9767<YZPJ_#WT
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M,D*?A0U0[TKB+^+,Z8+7T2%"",GKC:X!(NE!I A*&@X7'J6694 =G544FTC
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M9]]."\*X]*&[>)'C%8NLE65UBGHT3_:>>J0P\V[U_9>/'Q.Y#F$Q[[2L?^?
M[CO"K5IDVUJ%>.,^FQ$ 6099FSD+DPQQ@_%A& F'" /^W!@7",'E AG 54Y]
MJE;C#%8S2Y/ G^C(DT 1Y<03QF2EA+9,3%GA'^"+2M)UL%'3R!(,]\B<)F/*
M ,"["U/23B,J+R#&RPFI<B$HC<Q<&!;FKCMK5!D.R@\,8L30OC8Z2L296O,#
MDVCC9<1;*^:6,'T2;T.5,QN1D?I&V!4-++-,+>N4X:3[QGN?\MU1FV?5?3/\
M[)L-,F&$V[(,1N/8+=.[I"I3SRB&(-<?4Q"[["H#]'79K.TM?W1V\O3I8@2E
M$8!$![5EN [3B=6G5[BMD_I5\H_CU[RC/6#.2>$7%^459+CI9SK>FKS![#3@
M("M4?84W+OP:5AW#]S<!M8V):DU47SPTH_)E.0 B$8C$(JL9R!-H&4PNOMIX
M/ANQFA>0RI18Y98KA-**3 AA[?VPL =<=)U"M/1VR+R.(,VDZC, FP%7A%(Q
MX7/@TB5[-9OX>M",J*@I=7/)R<A$;@O\H'"%CWI_C]^2BG.UB8X?S['9C&HM
MI#SQ:/92 TB-P7=NQ!#,"QOS(X)M^+7<$4P+ AP;-&Z@WJV*KK;O8F-EMJLH
M#5OL\QUB:@D7^2+K$:J^HGIAUA38.(ZWD$^X42@;A3(GE())1\O1-B[\D,-U
MDZ.C4DI/%!<$&.W@*%D*Y3!O0WR%,^9Y$?9<N40[O7($T53SGQQHX_GWR."D
M#L>.,]DJ,!,K\$R T@8(*,SE.S5ZK"J YL[8]&5%90KFWSTF<C%GTR6IJ"X(
MS6CG5T4,6_^Z[S )D)D855V$'\\"?V(5QT'[,=T!1G*=SX.NN3/?E[7>X\\L
M0(,D6&[\!,:&_WIJ5]4+(,<WU&C1J".HM+S/O?),;4JL.D06(?ZZ5/PVL^-L
MWHMISSJT,1E@><$)K%P1\&M#Z-4;MK?<*T@<(5B 1"UF._ME.3%75>X?#KI4
MKL ?<C=K9/4'2#6)I.37EZ*E?<^8GZM<S]"YQ(E?0P0#1F$)9S)WWMR9>29#
M:Q$.N/L%U(>2U%[D@UXL2USEPPQ)2STSA$I]VBR0'29VFIL47$<=3M8C_S0-
M:$;$.,&SKJBL).#LD2Z+4YYR:2+'6VQ1HB)N,PNXO47\S4C#:9SF"Z3PDF=@
M^ K#1DDYIM>?@TL.L2>E<I9U\(DU'@K'V+-/*956NPB(+J=4598Z+,"%>0C8
M3EPFKZS>4"<OLFAVP4C0O1A[4==3(:G%[R]:1R\H"^MN!FC.0WVAB4PE2)4R
M.XNC"H5XA^8V/3&_T 5Y-!$\>+  BK*-];>M/X0@I1'@A747>V=/'^UWNCN=
M_1TC,)TW._.+,,)%'968FM !2GM1X]VL)0)7,$M@4LFMF"A-;4V.#R1 ^#T0
M7T?"MS.U&7!?]94Y(QDG33\9[!QL<5%/D$]NPFQ=3(O'UH]5FJ?OCISH,HDX
M&/#9=')A['H\ .X*Y&>)M2.DAA/'<UY6?A9G0K5O:433I7X%+!\LYB-%IK<T
M9DCQ1&A_O+6H9'9%';&U(@,(PZ'-]]_-SF]OJ62%V&Q:++U(,<G&:J=IDQZ[
M3I? TCI(]M.:"$2CY;A--26'Y>F.TH%8(KB*[0J2X78;G[*KE1>]DR)?X.!B
MTW@YE6BCS?+6:YB*+@-F;Z[8&(&Q42CXFMX(RC@LA<TKV?7#)^+?X1$H+!C;
MGY0[KS#A$Y"ORT*":3_/:LNZO%1 )SA&@L#J:S[Q51N5$TZ0O='HM%R??EOQ
M3BI" COJL?I3D=O(<T4#-Z23V<R;YZ"*1E1;759.3RJ51ZM]8Z\B+HBVL#^\
M41>O->YGVX*_HM103#?:OICMK;GO"M-L-B<-MG/5$]\^I_L*=B=-AGEU#O^%
MDF7 (\M\>FQD$,Z\6X]6%UYA%CY(20:6))?LLQE*\7?R^7E?L=7'F%GE('@"
MUU9CA] 8Q,?5103O>%,"/;WYMB!UU\I*;N<Q#9LQ9HN%9$#QEE2DY+*49)JL
MDO-[]%;05&(E!41G#I<L;[>Y]_/! .R#7(P*IVY(I^1A?Y3:+-1 3A[F!DMH
M,S$\<PE*CDS>)1_;SRZIF\JJ4?7,G5<J%B#9/5SS2SPW^/&8$&*P)BJ%P1O@
MU@$OBC63&#3S7554%,OXF*MJBV9MSGKKF;Q&J4%=2D0>+A7N1+!Y"?-O3OB;
M,;FHF?)PFKU"<M+LIXU=Q+%_*96JS#$]S^ I?MQPD79L"P5$FL)D%%[Q"]12
MH1"F*KR/4E'H\'Z;0WX/&_;;G+XK=($BW2T9IY!F?FD:^]]4<  W77F;):R<
MIH'?1#:NM<T@\;H,8JZ'"V'8>MR:Q@ZI*VS7*AP=^#WVI(5GBUGKP@9$:77*
M4">1FT8_)+8URMF<?C>2^5S*54V#F:YK0CG(OF*::68.%ZF]7LXOHUY5?.@0
M"YJ-EV+<-N,*DPO]#<2+/D<%QR7XN/5T8'4Q^,W&"/M?JVG-E(OQ=.!Y><8)
M[%JYX!M@%M[40+.==:%R2;BLFV60S8Y.*;VD]8JV;&UO>3U;N![MJV5O(EJK
M]3?C_7:1TVG@ 7L'NVO6KL9*3]NVXT4+X*1-P*+:WNKEQD+LU4EIS41;_%*K
M7D_*%//*^OVV$DEIA';:O;'4OP==FY^Z*167O'GZY J2H%[UDE;:MEWXWH\M
M]R#:9F!:1 ECMA]F8*!/QN456L>9,0"P1@I\5ALA,HNBVE14@!JN0VL4?(GW
M$1M#RHC"98E!=W<*S+X)G3-'2V,7(Y?=E7 #0H>A^0]%;K)!HXN;2!GA ;%:
ML7O9H=B"6$_NW%C[U0@-_M0:,<8\(2<J2-Z3X ZR*SLW)+6''P0>XAYF>-SW
M _MR1.!NPRA6K+;#3$[.)5G-DZ17<F4%%MBC/C>F=3='!<JFC9S](*B]O=5.
MPPI/Y/(5*&8 XRAQ>$&/]QCOI^/[[7HBX+V80R4=LWQGZV)W*9@=D5'0\@ZP
MVW!FJ+J)R!6S6&-RP<TV3L?DS]H4BQ'QR04X3L97F5S4.UP!33:-3LH!TXBM
MUO:K@]LUX8Y;=-3:,,T'OS9&W[0L#D85;&WPO'"<2YR'Y3\2_>8P5W4)9MHF
MSGJM.*O*\N[8E"_Y1^9@VE_T7 !^G%&Z%_?>E9I9.TQ).2K#D;27<"%M/#'+
M6;6IF8<93!>L=3'%*&""-SKGO%@B"/P BOUMM@ B2JD;-C[A# \?1/FF%9DJ
M9=6E/U&<.(WY=[$14?YCD ,Q3]*ORB%^25=/S"GX^E-WRMCBKX?.ATG%8?=$
M:.G/\LNGDQCKXBG6[DVK_(;TEFME,0FFULXIF7#MVVHP_&X$C_VJP_7.5%@$
M3JH""Q> 7Q)TRPF:N@GL'.(F?1_[9OD<CE]WCB7/9#T+,RVRX+&8%"/3??M/
M=!SK2=DKJ-4".W6@$@]"I."-&=W9)T>=NZ9VH+DBRH?0RE"8++SMM"3\217K
M.@%%C_(*T*:2MVR7?D'W^\:D?-<%-_V5X93N!]ST1O[6>RC+F5:$PL9V4;,6
MS:5BC+D@B%/0&\=HN11=D>A',;'E% 3\]&/#C]Q4;_]UJ[<=JB.8K>_^F!:7
MV0#$[(3S_JXBS'P(3S59N!?9)85)H7H/NS/R"4.>^4 \VUOSRC&>98_V.V<+
M"L':>NXWG7(;&=8RK&6F36Y!7,-LDE>@03W43W0/]3+5N1L!W C@:R\MYB0P
M"42O'I?3:!LXA!228CC,>X@%0._G!OI8)S<5/2[X1BS]3"-(O1A+,J"6NZ(1
MKY=O7<"7$" 0<5VABF-L?)IN,<9X/<@&!+2+>O$#.E5^GE4]K/5&6R5711J\
M/)4_G>TM+#;AW#RP8YW9,>>#.K^"^%[2HP)]:,9A+A;59 =9AFPP@?E"7X&1
MZ0FEC8:8^*MFTO\.P: A0$!4A I342,\5.8VF^:AK&5GUQ52'\>W0\E#QJB?
MV5EI;M%%%RIV$BX);8?W:;ZY3S?J[!;4V?5Z]]KU'D?\SW(SO)%+#6YOJ4X*
M295!JPWED*IR>DXY(BA?);5998U&#*GC?;EG?I[IRD]=Q:N(]);/I2R#^;0Y
M,)L#\_ID.IGO0RW4]:L[3Q<;9;^1W5N0W69Y7%R18]J,6_' #)0*%->%9&OA
MN&I<%4]B&9@JPEW$4U#Z_7A8H"))0LHKRCL$OLC5]MF13 ?&6C1S,Y;8]=^W
MN0.6.$?[>_,.TL%?XR#Y9:KMUM!B[+:-S&UD;EF9B^#5M(A>^>-J$*;+$#_M
M/UXUUX$=(@Q("NVZ^*,T*\MO8$K&DNJE\VK?[F9\T@L(];@7QC*S/7&V5Y=*
M=[M0LPRYE1;;#Z=0F-^3%U(9ET.^8A[=%G5?_WS'6.&=)A>S,5RE71XM-MO[
MA=,8#P'NLL(A+:]UJ!Z"TI7&-+4MB^#OW8/0>.$TB6F1) % 2+3FNU'B'>2S
M_X(J?6..&XU^E8W;#? :>00NL"E#=^XI%-*R 6!BNS$Q[GMU40)J Z&(0F*8
M.PJ-#BZ'1=<8S_57,$IB^$4MP&?QF&ZLN0YCQ BC8CS?R8 ;2]6CH $J(QUK
M8ZP/ GK[J,'?U"!F4FGYN+M?)^?%93[B8MIAC,YIB5;V@1]\^VM4#-X#??.;
M>Z)O=IW $!+]! 161*!Z3X4U7*?V/; &Z]7[T:[875)I_I27E='%O^TF;XKN
M5[-/DZQO+)#CX^.[)\=\#XWY[W:3H_(B-R;9Q]VWNVGR=C<YN2@&=\XA^I.Q
MUW-Z^^"_R@R:,5Z909Q<F%'<_=2/+LPU-3&JU\S:C&!:C<I97MWYI#\6W8LL
M'\ B ['E65Z=W_U<?RL&@R(;)H>[R<_9>3V!0O([9XC-!N.+Y'0TZYFK+F/A
MNONI$ITHZKOU'-^3'))%'[/L?&VB^SE'T%6PH'+@[OGXYLWIV@3W#3C7=S[%
M4V/!9<G_P4NCU20QV_OI[?^87_[\Y>.'U_\?4$L#!!0    ( $: RU#YH]&+
M9 @  .(8   0    9#DR,S0T-F1E>#4Q+FAT;<59;4\;N1;^'BG_P<K>6[52
M$O("W0(A$@0*V4T!D6Q[>[\Y,\[$W1E[-)XAS?[Z?8[M24("4:]$]R(^,![[
MO#[G.6=,[V;R:=3OW5R=7_:KE=YD.!E=]:_^TSAJMGL'[@G+!_X]ZUW<77YE
M%]>#N]'=PUGMR\UP<E7KLVH%FP9"Y2+K]RZ'G]EX\G5T=59;R#"?GWQH'DE5
M8SR6D3JKQ6*6UZRL^W);PK-(JD:NTY-6FI_ZQZG.<YW0"FVW*H:?KMGX87!6
MBXX[W</#]T;QM-5JM9O?TJC&SD>3L]KH[OK.B3^X[S^OXSUTL!TEIVRF5=XP
M\B]QTEX_SW@BX^7)1";"L%NQ8 \ZX8J4#:]OSVJ9C.:PKW?1O_H^EU.9,T0.
MNB_ZI!\F/V= N_,*%O1_*Y1XHZ8F/6VWZZS3ZK3V^/PZ*@<\$Y??ZVRH@B;;
MXV#K-92UV40O1,;N8QZ(/:Z]BK*Q+O(Y&W/%/F9<!=($NLX&Y^SXL/6AM<_5
MUPGLB(<2*UR%[!IE%(M$J).?#.'^%\'F_%$P'N0B9-RP0!?*B)CEFFUFNEZM
M<'8I8K[ (C9EJ<YX+K5B;_.Y8&]^:1_^>HH*Z W[ YVD7"U[!\,^U0"]^G#Z
MKLZDPCFE1&"/+21B34?33*3<RR+?9S*6*EJ_'XN@R&1>AN;J>S#G*A(,:A)I
MS$LF^'=;5K"TR$S!54[^/12Q8(>=P[?3=TS/K+(,2TY/)J(BME:9:L6_W3#E
M/,CI3/NXVZU3V#B2%2*".Z9@XTXD<)##;VU2!*,PS!1I:M.=UUG(*1$;==WR
M=;TC^7XM8+P2L*,+?M)!GQ1:?G]JV(.(I,E]U,<Y=-)AAH>/.DM8[^/=[02,
M7E+X7.:B85+4X(G2BXRG*)9&]WS\T#N@G7WV]J-$+-VQ/8=N==-YU>UV&YWN
M<>OP^%TI0H-&I>)QO"0(( 8K!&QDND"0,[MH$Z V G7\4IR>]W4G4)1T'*U6
M,J"<<K!.T&Y6O#("=1 7E'B@FQ2_$%B>V[<YRH^A/VSX.A4!L,/$;$:%@4K<
ML?^"&\'6R7YJ.)E-28X$CF7KF#T+CKIS\'D0[03$QH%*T4-(P\2,GJ?+34@1
MFHN4-G7KQZWW]<Y1BYDY6,+LNC*VZ]LUZ:MK"Z(!LHX8FEP'?]89*((]\K@0
M[%^M)KH]2^&M5</>;E>^C3Q.;7L$"D..G:T@>1Z&DM+$8W;TX:A^W/V5.?M0
MC]-OB(G?IQ]%UD"N=.YJ)+6YC= B"!,^.!:8"Y"#R$SI4!FP)IL0>3C99/%4
M4!B-CE?'C8 2&/)$C (P"%@.FQO,10OKK22+1YGP2(/[T9/\X'"U<@UE('QT
MMV!N'(;?\"0]Q:XF&XT&5L5OPEH,*[%B:<URH@!%&\CFA$_KG2F"^1-;RPKA
M]O6/L-<?F^:?E^9OI6SO@/$Z77?X7%>2<".5"BMUMO =4GR'!$4^VNX02T%8
MTOO*OKY5BN[Y><_KS]1 M7+NVPKI?! FMT$>B"R7,QG@@:*-]KQNQYO-:,5I
MVZ7UK-2+)9J[>7I> "UV*"BRC$:2)=&<HZJU\)+,$+,,L4P)/X$ST=6'+E"J
ML,[,N(MRB:!,P/*0P*.#@H)@4*/!VCN\240"SU3(K3IM24XJA-KM)^-@$FGX
M5H21JP!4&/(IC.'9DFSB*:@\S23%"^8(Q:=H5F!&/&1BU5%\QI%HPKN![5,1
MZT63G=N=9!>'+G*B0*DF/'?(+P&RB0G.@J=)(AZ9X1&ZGM*=]8O.5RM*YW F
M%"G99*,-4G!1M.'R&IML-;094Q!%D+A(J +P5+#<BN2892%$!C*W% T"6X>9
M&"Z1N>>OPH9QE<9U9E$8,XP#)('2N,[S#XCS0*"$"3W[!PKY#A@H4XCZC24L
M6O.SCQWS8">KI)LWE=X\)I/49A&P23AU9V0$G)A9-"RU#TPIS4,%F7)RFVS3
M"J]$HH[7F +K"^RW1(.EU/<9DCH3H6T"5(<E2OY0U@M+*6:5&'P?V)V#C3E\
MQ!?E(;N;'LJ!W4+&U@4@YB!ONP9U;V\L=R#7Y#\^?H2SD':49B$DUDLL MD9
M+T*RM&YG9GJYGIA7HT.U IEF-377:5O9\;@[A<&NL/I62-E*Y)13V!S/8A"R
MP7%5[XC(O[(-B#D9#L&HRQ#?<#&7B?-T&LO(V4>-/7R4$+?4!06*BAKF!3(#
MI.$E#,(CFC*A&U:&^#/6J4,[)EM4(ZGB,\"@!,HTTT4TSSWC8=@ 1M3JL\8=
MHJT\QB&8Z*W'>1W*V?(%#G(@L@GTBYN(=5E;S-WT1Q)*\)#'&)I  $@*L6,F
M32@]__K=G"*G$05)?..8AD_UH\,*:#,&?Q%7ECGS<Y&#/_OG2MME&$B0J\(
M,8E( V,NV=*"3FX@R;5N<J0<QWS,X+>;QMU$5J?P*8M#WQ+M8,8C3GT&,5S:
MKF*%S@BPB'I ?8MT52NKB?NEMKZ0H$K  ].K#*F#6D5U-BMH_$^Y##T-*= Y
M-2T$O+G]V;\1KL[Z=FS/99D;O_9?F.P>V[K1VG_CUGGIQHTN"R^'GS'(^>M
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MHM[O81M\1-Y=?L6B_=_&WU!+ P04    " !&@,M0&_HQ)$X*  ""'0  $0
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M 5!+ 0(4 Q0    ( $: RU!H*.Z18P,  "H,   1              "  0
M  !C9&YA+3(P,C P-C$P+GAS9%!+ 0(4 Q0    ( $: RU"N!-/O8@8  $E$
M   5              "  9(#  !C9&YA+3(P,C P-C$P7VQA8BYX;6Q02P$"
M% ,4    " !&@,M0;"%2\+L$   )*P  %0              @ $G"@  8V1N
M82TR,#(P,#8Q,%]P<F4N>&UL4$L! A0#%     @ 1H#+4%%3ZM/+%0  E),
M  X              ( !%0\  &0Y,C,T-#9D.&LN:'1M4$L! A0#%     @
M1H#+4'SHT&?LOP  ,^P# !               ( !#"4  &0Y,C,T-#9D97@Q
M,2YH=&U02P$"% ,4    " !&@,M0^:/1BV0(  #B&   $
M@ $FY0  9#DR,S0T-F1E>#4Q+FAT;5!+ 0(4 Q0    ( $: RU ;^C$D3@H
M ((=   1              "  ;CM  !D.3(S-#0V9&5X.3DQ+FAT;5!+!08
1    !P ' +P!   U^      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d923446d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d923446d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cdna-20200610_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdna-20200610_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cdna-20200610.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cdna",
   "nsuri": "http://www.caredxinc.com/20200610",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d923446d8k.htm",
      "contextRef": "duration_2020-06-10_to_2020-06-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d923446d8k.htm",
      "contextRef": "duration_2020-06-10_to_2020-06-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d923446d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cdna-20200610.xsd" xlink:type="simple"/>
    <context id="duration_2020-06-10_to_2020-06-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2020-06-10_to_2020-06-10">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-06-10_to_2020-06-10"
      id="Hidden_dei_EntityCentralIndexKey">0001217234</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-06-10_to_2020-06-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-06-10_to_2020-06-10">2020-06-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-06-10_to_2020-06-10">CAREDX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-06-10_to_2020-06-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-06-10_to_2020-06-10">001-36536</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-06-10_to_2020-06-10">94-3316839</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-06-10_to_2020-06-10">1 Tower Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-06-10_to_2020-06-10">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-06-10_to_2020-06-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-06-10_to_2020-06-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-06-10_to_2020-06-10">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-06-10_to_2020-06-10">287-2300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-06-10_to_2020-06-10">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-06-10_to_2020-06-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-06-10_to_2020-06-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-06-10_to_2020-06-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-06-10_to_2020-06-10">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-06-10_to_2020-06-10">CDNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-06-10_to_2020-06-10">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-06-10_to_2020-06-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d923446d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d923446d8k.htm">d923446d8k.htm</File>
    <File>cdna-20200610.xsd</File>
    <File>cdna-20200610_lab.xml</File>
    <File>cdna-20200610_pre.xml</File>
    <File>d923446dex11.htm</File>
    <File>d923446dex51.htm</File>
    <File>d923446dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
